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THE ROLE OF CURCUMIN IN HUMAN DENDNRITIC CELL 
MATURATION AND FUNCTION  
Shawna A. Shirley, M.S. 
ABSTRACT 
 
Curcumin is the yellow pigment found in the Indian spice curry. It has anti-
inflammatory, ant-oxidant, anti-cancer, anti-viral, anti-bacterial and wound 
healing properties. It is widely used in industry for its flavor as a spice and as a 
coloring agent because of its brilliant yellow color. It is also used as a dye for 
textiles and as an additive to cosmetics. Dendritic cells (DCs) are the sentinels of 
the immune system and functions as the bridge between the innate and adaptive 
immune response. The effect of curcumin on DCs is poorly understood. A study 
shows curcumin prevents the immuno-stimulatory function of bone marrow-
derived murine DCs, but no study examines the effects on human DCs. This 
study investigates the effects of curcumin on immature human DC maturation 
and function in response to immune stimulants lipopolysaccharide (LPS) and 
polyinosinic-polycytidylic acid (poly I:C).  
Human CD14+ monocytes isolated from the peripheral blood of donors 
are cultured with GM-CSF and IL-4 supplemented media to generate immature 
DCs. The cultures are treated with curcumin, stimulated with the above 
 xiii
mentioned stimulants then functional assays performed. These assays include 
homotypic cluster formation, surface marker expression, cytokine production, 
chemotaxis, endocytosis, DC-induced allogeneic CD4+ T cell proliferation after 
mixed lymphocyte reaction, gene expression analysis and immuno-fluorescence 
labeling and imaging. Curcumin-induced changes in gene expression indicate the 
actin cytoskeleton signaling pathway is a target. Immuno-fluorescence labeling 
and imaging of f-actin was carried out.  
Curcumin reduces DC maturation in response to the stimulants used in 
the study. Expression of surface markers, cytokines and chemokines is reduced 
as well as DC-induced stimulation of allogeneic CD4+ cells after MLR. Curcumin 
prevents chemotaxis without affecting chemokine receptor expression and 
significantly reduces endocytosis in non-stimulated cells.  Curcumin-treated DCs 
do not induce a Th1 or Th2 population in allogeneic MLR but induces a 
CD25+Foxp3+ regulatory cell population. Immuno-fluorescence imaging shows 
curcumin causes the cell to become more rounded. These data imply that 
curcumin inhibits f-actin polymerization and thereby prevents DC maturation and 
function in response to stimulation. This outlines a novel role for curcumin as an 
immune suppressant and shows its therapeutic potential as an anti-inflammatory 
agent. 
 xiv
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INTRODUCTION 
 
Turmeric is a bright yellow spice derived from the root of the perennial 
Curcumin longa, a member of the ginger family. Curcumin, also called 
diferuloylmethane, is the most biologically active compound turmeric and belongs 
to a family of compounds called curcuminoids which usually comprises about 3% 
of turmeric powder. The spice is widely used for its culinary flavor as it gives 
curry its characteristic taste. Its use also extends to medicine. For centuries it has 
been used in Asian cultures in Ayurvedic systems of medicine most likely 
because of its properties as an antiseptic, analgesic, appetite suppressant, anti-
inflammatory agent, antioxidant, anti-malarial and insect repellant (3, 49). In 
industry it is commonly used as a food preservative, a yellow dye or coloring for 
food and textiles and as an ingredient in pharmaceuticals and cosmetics. 
Research shows curcumin has anti-inflammatory, antioxidant, anti-
parasitic, anti-viral and anti-cancer properties (12, 74, 88, 91).  It targets 
transcription factors, cytokines, cell adhesion molecules, surface receptors, 
growth factors and kinases, among other molecules (9, 72, 78, 152), and directly 
binds to a variety of surface and intracellular proteins causing direct cellular 
pathway inhibition or activation of secondary cellular responses (3, 48).  
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A Natural History of Curcumin 
Curcumin was first isolated from turmeric in 1815 and its 1910 its chemical 
structure was determined as C21H20O6 by Vogel and Pellatier (145). The history 
of curcumin however, dates back over 5000 years to the time of Ayurveda. 
Ayurveda, or the science of good life, is an ancient system of healthcare 
practiced in India. In this system of medicine curcumin was used for wound 
healing, blood cleansing and to cure stomach illnesses. Also known as Haldi, 
curcumin has been used for centuries without known side effects as a food 
preservative or additive for coloring and flavor. It can be ingested to treat a host 
of internal ailments or mixed into a paste and applied topically to treat wounds, 
bruises, boils pains, sprains, swellings and other disorders of the skin (61). 
Curcumin is a valuable export crop and is widely cultivated by Asian countries. In 
addition to its culinary and medicinal uses, it is also commonly used in industry 
as a food preservative, a yellow dye or coloring for food and textiles and as an 
ingredient in pharmaceuticals and cosmetics (128). In Hindu religious 
ceremonies it is mixed with sandalwood powder and applied to the forehead (61). 
The earliest entry about curcumin in PubMed is from 1949, a study 
published in Nature explored the antibacterial action of curcumin (115). To date 
there are 2438 articles in PubMed related to curcumin.  
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Curcumin Classification and Structure 
Taxonomically, turmeric belongs to Class Liliopsida; Subclass 
Commelinids; Order Zingiberales; Family Zingiberaceae; Genus Curcuma; 
Species Curcuma longa (ref). It is a hydrophobic, polyphenolic compound that is 
soluble in ethanol, dimethyl sulfoxide, acetone, chloroform and oils. Curcumin 
exists in both keto and enol forms, but the keto form is more energetically stable 
(Figure 1). Its absorption maxima is around 420 nm and therefore it fluoresces at 
the wavelength of FITC. Most commercially available preparations of curcumin 
contain other compounds such as its analogs demethoxycurcumin and 
bisdemethoxycurcumin (3). Though curcumin is thought to be the most potent of 
the three, it is unclear whether the other analogs have similar activity (4, 127).  It 
is suggested that the combination of all three is more potent than each 
individually (58).  
 
Molecular Targets and Receptors of Curcumin 
The lipophilic property of curcumin allows it to rapidly permeate cell 
membranes and enter the cytoplasm (62). There are proteins to which curcumin 
binds and initiates secondary cellular responses. These include, among others, 
5-LOX, serum albumin, iron, IKK, PKC, PKA, GST and autophosphorylation-
activated protein kinase (3). Due to its size and chemical composition, it is 
possible that curcumin enters cells by passive diffusion though the lipid bi-layer. 
Its anti-inflammatory properties are ascribed to its ability to inhibit transcription 
factors such as NFκB, AP-1 and STATs, its ability to reduce COX-2 and 5-LOX 
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expression and its ability to reduce the expression of surface adhesion 
molecules. Its role as a potent antioxidant may also contribute to its anti-
inflammatory actions (3, 15, 118, 143). Antioxidants are compounds that delay or 
arrest disease progression. Curcumin functions as an antioxidant by inducing the 
expression of reactive oxygen species (ROS) and binding iron (39, 155). The 
structure of curcumin is rich in hydroxyl and methoxyl groups. There is some 
debate over whether it is the methylenic group at center or the phenol groups 
that contribute the hydrogen atom that confer its antioxidant property (16, 65, 
107). 
 
  
 
 
 
 
 
 
  
 
 
 
Figure1. Structure of curcumin (diferuloylmethane) in both keto and enol forms (reprinted from  
Wikipedia) 
Keto 
Enol 
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Anti-inflammatory Activity of Curcumin 
The anti-inflammatory property of curcumin is thought to be responsible 
for many of the activities associated with curcumin.  It has been suggested that 
this property is directly related to the structure of the molecule, though there is 
debate over which portion is responsible; the diene bonds in the center or the 
phenol groups at either end (12, 27, 28, 70). Another notable property of 
curcumin related to its role as an anti-inflammatory agent is its antitumor activity. 
Curcumin can alter multiple signaling pathways by interacting with a number of 
molecular targets (3, 10) and function as a chemopreventative agent. It 
suppresses multiple forms of cancer including cancers of the breast, colon, liver, 
oral cavity and prostate.  
Curcumin inhibits proliferation of an array of tumor cell types in vitro (2) 
and prevents metastasis in an in vitro model of mouse melanoma (93). It 
interferes with angiogenesis by inhibiting fibroblast growth factor (FGF)-induced 
neovascularization and inhibits vascular endothelial growth factor (VEGF) 
expression (13, 52, 94). Adhesion molecule expression is important for tumor 
metastasis. Curcumin may mediate its anti-tumor effects partially by reducing 
adhesion molecule expression (19, 138). Curcumin also modulates matrix 
metalloproteinases (MMPs) that regulate endothelial cell migration and 
attachment (82). Curcumin affects multiple signaling pathways including key 
pathways regulated by transcription factors NF-κB, AP-1, Akt and Nrf2 (2, 54). 
These pathways control the production of cytokines and other inflammatory 
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mediators, cell proliferation and apoptosis. Modulation of these pathways by 
curcumin has a direct impact on tumor progression and survival.  
 
Pharmacology and Pharmacokinetics of Curcumin 
Turmeric has been classified by The Food and Drug Administration among 
substances Generally Recognized as Safe (GRAS). It has been shown to be safe 
at high doses in humans, rats, mice , monkeys and guinea pigs (26, 116, 117). It 
has also been tested for mutagenicity using the Ames test and has been shown 
to be nonmutagenic (97). Curcumin has been safely used as a dietary spice for 
centuries without adverse effects. An estimated 200mg of curcumin is ingested 
daily by Indian adults (29, 49). The only adverse effects noted in the literature are 
rare cases of allergic contact dermatitis (46, 53).  No adverse drug interactions 
have been reported (49).  
Turmeric contains turmerin, essential oils (turmerones, altanones and 
zingiberene), curcumin, flavanoids, resins, proteins and sugars. Curcumin is the 
most biologically active compound found in turmeric and comprises about 2 to 8 
percent of turmeric preparations (137). It is estimated that about 40-85% of 
curcumin remains unaltered after ingestion in the gastrointestinal tract where it is 
absorbed by the intestinal mucosa (109, 146). The oral toxicity of curcumin is 
low. Human clinical trials indicate no toxicity at doses as high as 12g/day (11). 
The oral bioavailability of curcumin is also very low due to its rapid metabolism in 
the intestinal mucosa and liver. Humans given about 3g/day had undetectable or 
very low serum levels (119, 122). One study reports a patient with a serum 
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concentration of 58ng/ml two hours and 51ng/ml four hours after receiving 12g of 
curcumin. Another patient had serum levels of 51ng/ml four hours after receiving 
a 10g dosage (79). 
The degradation kinetics and stability of curcumin in physiological 
conditions vary. Degradation is pH dependent. At neutral or basic pH, the 
degradation is rapid, while more acidic conditions promote slower degradation. In 
0.1M phosphate buffer and serum free media curcumin is degraded by about 
90% over 30 minutes. In culture medium containing 10% fetal calf serum and in 
human blood only 20% of curcumin is degraded after 1 hour. After 8 hours 50% 
still remained (148). Byproducts of curcumin metabolism differ based on the 
route of delivery; when given orally, curcumin sulfonate and curcumin 
glucuronide are produced but when given intraperitoneally or systemically 
tetrahydrocurcumin is produced. It is unclear whether these metabolites are 
biologically active, though tetrahydrocurcumin is active in some systems (103, 
104, 130) but not others (60, 98). 
The rapid metabolism and poor bioavailability of curcumin impedes its use 
as an orally delivered drug. A study by Shoba et al. showed that combining 
piperine, a known inhibitor of hepatic and intestinal glucuronidation, with 
curcumin significantly increases its oral bioavailability in humans and rats (122). 
A more recent approach is to use polymeric nanoparticle-encapsulated curcumin 
or “nanocurcumin” as a novel formulation to deliver curcumin (20).  
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Curcumin in the Clinic 
 The ability of curcumin to modulate multiple molecular targets, coupled 
with its pharmacological safety and low cost make it attractive for clinical 
research. There are currently about twenty-five clinical trials examining the 
therapeutic potential and efficacy of curcumin (www.clinicaltrials.gov). These are 
outlined in a few review articles (10, 45, 54). Initial results are positive in some 
subsets of patients when curcumin is used to treat cancer and inflammatory 
conditions including idiopathic inflammatory orbital pseudo tumors, post-
operative inflammation, external cancerous lesions and pancreatic cancer (33, 
75-77, 112).  Other disease targets being considered include psoriasis and 
Alzheimer’s disease. 
  
Dendritic Cell Biology 
  Dendritic cells are the sentinels of the immune system and regulate the 
immune response. They are widely distributed throughout the body and exist in 
two functionally distinct states; immature and mature. Immature or resting 
dendritic cells reside in peripheral organs where they monitor the surrounding 
tissue for invading microorganisms. They alert the immune system to the 
presence of pathogens by engulfing them, processing the foreign proteins and 
presenting the peptide fragments on their surface. After DCs are activated, they  
mature and migrate to the lymphoid tissue where they prime naïve T 
lymphocytes and stimulate a specific or adaptive response (50, 92, 129). 
Immature DCs express relatively low levels of co-stimulatory and antigen 
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presenting molecules but have a high endocytic capacity while mature DCs 
express higher levels of these markers and a reduced endocytic capacity. 
Maturation of dendritic cells involves changes in gene expression, activation of 
signaling pathways and substantial cytoplasmic reorganization. mDCs extend 
long dendritic processes that increase the cell surface area that enhances the 
opportunity for T cell interaction (92). The changes that occur in the DC during 
the maturation process are regulated by actin assembly and disassembly 
mediated by the Rho family of GTPases which include Rho, Rac and Cdc42 (24, 
43, 100, 124, 133, 151). 
Maturation of DCs is a key step in the initiation of immunity. Decreased 
endocytosis, increased migration and the increased ability to stimulate 
proliferation and differentiation of T cells are characteristics of mature DCs. 
Another characteristic feature of mature DCs is their ability to form cellular 
aggregates or homotypic clusters (37). Cluster formation has been observed in 
vivo with cutaneous Langerhan’s cells as well as in vitro (31, 84, 150).  It has 
been shown that cluster formation is not an accidental encounter between 
migrating cells, but rather has a physiological function to enhance maturation. 
Clustering results in increased CD86, CD80 and CD54 marker expression, and a 
modest increase in the ability to stimulate T cells in a syngeneic MLR (31). The 
authors also suggest clustering facilitates antigen transfer between maturing 
DCs. 
Immature DCs are quite different from mature cells. They can take up 
particles, antigen and microorganisms by phagocytosis and they express 
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receptors that mediate endocytosis (64, 132). Once iDCs have captured antigens 
or particles, their ability to capture more quickly decreases. The antigens enter 
the endocytic pathway where they are processed and presented on the surface 
of the cell in the context of MHCII molecules (25, 106).  
Primed DCs will migrate to secondary lymphoid organs and present the 
antigen-peptide-MHC complexes to naïve CD4+ T cells and cytotoxic CD8+ T 
cells which induce differentiate into memory and effector cells. The mixed 
lymphocyte reaction (MLR) can be used as an in vitro model of DC-TC 
interaction. DCs will stimulate proliferation of the T cells in co-culture and drive a 
specific phenotype based on the cytokine environment and the type and 
activation state of the DCs (32, 135). The ratio of DCs to TCs will influence the 
phenotype of T cells produced. A low ratio induces a Th2 population, while a high 
ratio induced mixed Th1/Th2 cell development (135). 
DC migration is regulated by chemokine and chemokine receptor 
interactions with the aid of accessory proteins (38). The chemokine receptor 
CCR7 plays and important role in DC migration. Mature DCs upregulate CCR7 
expression to improve their responsiveness to its ligands CCL21 and CCL19. 
CCL21 is important in guiding the maturing DCs to the lymphatic vessels and 
CCL19 guides cells to the T-cell zones of the lymphoid tissues (30, 35, 36, 51, 
85).  
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The Actin Cytoskeleton 
The actin cytoskeleton provides the scaffolding of the cell that helps to 
maintain its shape. Most dendritic cell functions are controlled by cytoskeletal 
rearrangement. Individual units of actin, globular actin (g-actin), assemble in long 
polymer filaments to from filamentous actin (f-actin). Two parallel strands of f-
actin twist around each other to form the microfilaments of the cytoskeleton. 
Antigen capture, antigen presentation, cell adherence and cell migration is 
regulated by the Rho family of GTPases which regulate actin cytoskeleton 
organization (14, 43, 95, 100). The engagement of T cells by DCs is also 
dependent on cytoskeletal rearrangement for formation of the immunological 
synapse (5, 6). The Rho family of GTPases belongs to the larger Ras 
superfamily of GTP-binding proteins. The Rho subfamily consist of more than 
twenty distinct proteins including RhoA, RhoB, RhoC, RhoD, RhoE, Rac1, Rac2 
and Cdc42 (124). The Rho GTPases function by cycling between the active 
GTP-bound state and the inactive GDP-bound state (22). Regulation of 
endocytosis is in part due to the levels of activated Cdc42 (43). Cdc42, Rac and 
Rho are involved in antigen presentation in DCs as well as motility, adhesion and 
chemotaxis (7, 8, 124). Regulation of the DC cytoskeleton is largely 
developmentally regulated (24).  
The Wiskott-Aldrich syndrome protein (WASP) is the specific effector of 
Cdc42 (141). It is expressed mainly in hematopoietic cells and its functions as a 
signal transducer to the actin cytoskeleton (140).  WASP is also important in 
filapodia formation, adhesion marker expression and DC chemotaxis (7, 8, 140). 
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WASP binds the actin related protein (Arp) 2/3 complex. Together they regulate 
the actin cytoskeleton by nucleating the actin filament assembly to create a 
branching network at podosomes that govern the directional movement of DCs 
(21, 96, 154).  
Nexilin is an f-actin binding protein localized at the cell-matrix adherens 
junction that was first described in 1998 in rat brain and fibroblasts by Ohtsuka et 
al (102). Nelin (nexilin-like protein) is the human homolog of nexilin found 
primarily in the heart, skeletal muscle, artery and vein. Based on structural 
analysis, it can regulate the formation of stress fibers and focal adhesions (156).  
In HeLa cells it stimulates migration and adhesion and so mediates cell motility 
(147). The role nelin plays in dendritic cell function is unknown. 
 
Curcumin and the Actin Cytoskeleton 
Little is know about how curcumin affects cytoskeleton of the cell. A few 
studies have examined the effects of curcumin on the actin cytoskeleton in 
neurons, hepatic cells and cancer cells but none have outlined these effects in 
dendritic cells. In an in vitro study using prostate cancer cells, curcumin shows 
profound effects on actin-based motility and microfilament organization (56). The 
actin inhibitor chytochalasin B was used in this study as a control. Curcumin 
shows similar inhibitory effects. Cyclin-dependent kinase 1A (p21) functions as a 
regulator of cell cycle progression at the S phase.  p21-activated kinases (PAKs) 
also participate in the regulation actin filaments along with the Rho GTPases. 
Curcumin suppresses PAK translocation in aged Tg2576 transgenic mice with 
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Alzheimer amyloid pathology (86). Although this was an Alzheimer’s study and 
curcumin was not the focus, it demonstrates the role curcumin plays in the 
regulation of actin organization.  In another study, curcumin affected the 
formation of actin stress fibers which helps to suppress the intra-hepatic 
metastasis in an orthotopic implantation model (101). 
 
Curcumin and Dendritic Cells 
Outside of the work published from this study, there is only one article to 
date that explores the role of curcumin dendritic cells. The authors show 
curcumin inhibits the immuno-stimulatory function of murine bone marrow-
derived dendritic cells (69). The authors show that at non-toxic concentrations, 
curcumin is a potent inhibitor of DC maturation. Curcumin suppresses the 
expression of surface maturation markers CD80, CD86 and MHC class II in a 
concentration dependent manor and reduces the production of IL-12 and other 
pro-inflammatory cytokines IL-6, IL-1β and TNF-α in LPS-matured DCs.  
Studies have chronicled the effects of curcumin on antigen presenting cells other 
than dendritic cells. An in vivo model of murine latex allergy shows CD80 and 
CD86 levels are reduced on lung B cells treated with curcumin (73). Another 
study reports reduced CD80 and CD86 expression on macrophages treated with 
curcumin (121). The immunomodulatory properties of curcumin also extend to its 
effects on cytokine production in dendritic cells and other antigen presenting cells 
(1, 44, 66, 69, 152). Curcumin reduced levels of IL-12, IL-6, IL-1β, TNF-α in 
murine DCs, monocytes and macrophages. Pre-treatment with curcumin also 
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inhibits transcription of IL-1α, IL-1β, IL-2, IL-6, IL-10 and TNF-α mRNA in rat liver 
(40). In this study we investigate the effect of curcumin on human dendritic cell 
maturation by pre-treating the cells with curcumin and then inducing maturation 
with immune stimulants. 
 
Significance of the Study 
A study by Kim et al. reveals that curcumin impairs the immunostimulatory 
function of murine dendritic cells (69), but the effects of curcumin on human 
dendritic cells remain unknown. In this study we investigate the effects of 
curcumin on human monocyte-derived DC maturation and function. Dendritic 
cells direct the adaptive immune response to pathogens and allergens so we 
hypothesize they play a critical role in mediating curcumin’s systemic effects. We 
examine effects of curcumin on human dendritic cell maturation and function. 
Modulating the DC response could provide an effective approach to treat and 
control unwanted inflammation and could provide an effective approach to 
treating inflammatory diseases. Elucidation of the underlying mechanism of 
curcumin modulation will have a direct impact on allergic disease control as 
recent studies point to its great potential for protection against lung diseases and 
allergic asthma (71, 73, 110, 131, 144). Curcumin shows promise as an 
immunomodulatory compound for the treatment of allergic diseases. Kobayashi 
et al. reports that curcumin inhibits IL-5, GM-CSF and IL-4 production and inhibits 
the proliferation and IL-2 production in lymphocytes obtained from atopic 
asthmatics in response to Dermatophagoides farinea (71). Curcumin diminishes 
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the Th2 response, reduces lung inflammation and reduces eosinophilia in a 
murine model of latex allergy (73) and also reduces histamine release from rat 
basophilic leukemia cells (131). In guinea pigs it is shown to attenuate airway 
hyper-responsiveness (110). Curcumin presents itself as an interesting molecule 
for further investigation. The findings of this study provide novel treatment and 
control strategies for allergic diseases. Due to its low toxicity, curcumin would 
offer itself as a safe alternative to non-steroidal anti-inflammatory drugs (NSAIDs) 
and other inflammatory drugs currently available. 
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GOALS AND OBJECTIVES 
 
Purpose 
The purpose of this study is to examine the effect of curcumin on immature 
human dendritic cell development and function in response to external stimulants 
that mimic infection and stimulate cell maturation or activation. This study utilizes 
in vitro cultures of primary dendritic cells obtained from a number of donors 
assumed to be in good health. Lipopolysaccharide (LPS), 
polyinosinic:polycytidylic acid (poly I:C) or tumor necrosis factor alpha (TNF-α) 
were used to stimulate or induce DC maturation through independent cellular 
pathways. 
 
Hypothesis 
Curcumin has potent anti-inflammatory properties and prevents the 
immunostimulatory function of murine dendritic cells. We hypothesize that the 
same is true for human dendritic cells. We expect curcumin will prevent DC 
maturation in response to a variety of stimulants and impede cell function.  
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Specific aims 
Aim 1: To determine the effect of curcumin on human mdDC maturation in 
response to immune stimulants. 
? Does curcumin affect visual signs of DC maturation such as cell 
morphology and homotypic clustering? 
? Can curcumin alter the expression of the surface markers on iDCs? 
? Does curcumin affect the level of expression of the surface markers on 
DCs in response to immune stimulants? If so, is it dependent on the 
pathway propagated by the stimulant? 
? Can curcumin alter cytokine production in stimulated cells? 
 
Figure 2. Aim 1 experimental outline. Designed to investigate the effects of curcumin on 
human mdDCs with and without stimulation. Dashed boxes represent independent variables 
and solid boxes represent dependent variables. 
mdDC    
primary culture Model 
Dependent 
Variables 
Independent 
Variables 
• Cell morphology 
• Homotypic cluster formation 
• Surface marker expression: 
    (CD86, CD83, HLA-DR, CD40, 
CD54) 
• Cytokine secretion: 
    (IL-12p70, IL-10, IL-6, TNF-α, 
IFNγ) 
LPS stimulation (24 hrs) 
poly I:C stimulation (24hrs) 
TNF-α stimulation (24hrs) 
No stimulation (24 hrs) 
Curcumin 
pre-treatment (1hr): 
• 0 µM (DMSO) 
• 20 µM (7.4µg/ml) 
• 30 µM (11.1µg/ml) 
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Aim 2: To determine the effect of curcumin on human mdDC function in the 
presence of immune stimulants. 
? Does curcumin affect iDC endocytosis? 
? Does curcumin affect endocytosis of stimulated DCs? 
? Does curcumin affect DC chemokine secretion and chemokine receptor 
expression? 
? Does curcumin affect DC chemotaxis? 
? Does curcumin affect the ability of DCs to induce proliferation of allogeneic 
donor CD4+ T cells in co-culture? 
? How does curcumin affect the phenotype of proliferated T cells in co-
culture? 
Figure 3. Aim 2 experimental outline. Designed to examine the effects of curcumin on stimulated 
DC function. 
Model 
Dependent 
Variables 
Curcumin 
pre-treatment (1hr): 
• 0 µM (DMSO) 
• 20 µM (7.4µg/ml) 
• 30 µM (11.1µg/ml) 
LPS stimulation (24 hrs) 
poly I:C stimulation (24hrs) 
• Endocytosis 
• Chemotaxis 
• Chemokine and chemokine 
receptor expression 
Allogeneic    
DC-TC     
co-culture 
• T cell proliferation 
• T cell phenotype 
DC primary 
culture 
No stimulation (24 hrs) 
Independent 
Variables 
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Aim 3: To determine the effect of curcumin on actin rearrangement in human 
mdDCs. 
? Does curcumin affect the expression of actin and actin pathway-
associated proteins in human DCs? 
? Does curcumin affect actin polymerization and cytoskeleton 
rearrangement in human DCs? 
? Does the inhibition of actin result in similar functional observations to that 
of curcumin? 
 
Figure 4. Aim 3 experimental outline. Designed to examine the effect of curcumin on the actin 
cytoskeleton in dendritic cells. 
Model 
Dependent 
Variables 
Curcumin 
pre-treatment (1hr): 
• 0 µM (DMSO) 
• 20 µM (7.4µg/ml) 
• 30 µM (11.1µg/ml) LPS stimulation (24 hrs) 
• Microarray analysis of total RNA 
• Confocal imaging of actin 
• Confocal imaging of actin pathway-
associated proteins 
• Western blot of actin pathway molecules 
• Functional assay using actin inh bitor 
(endocytosis assay)
DC primary 
culture 
No stimulation (24 hrs) Independent 
Variables 
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MATERIALS AND METHODS 
Materials 
Curcumin (from Curcuma longa) was obtained from Sigma Aldrich (St. Louis, 
MO) and dissolved in DMSO (11mg/ml). Buffy coats were obtained from Florida 
Blood Services (St. Petersburg Florida). Donors in good health and ranging in 
age from 18 to 50 were used for the study (Table 1). The cell isolation reagents 
CD14 microbeads and naïve CD4+ T cell isolation kit were obtained from Miltenyi 
Biotec (Auburn, CA). For cell isolation and culture, Histopaque®-1077 and was 
obtained from Sigma Aldrich and recombinant human cytokines GM-CSF and IL-
4 were obtained from PeproTech (Rocky Hill, NJ). All other cell culture reagents 
were obtained from GIBCO Invitrogen (Carlsbad, CA). LPS, poly I:C and PHA 
were obtained from Sigma Aldrich (St. Louis, MO). CFSE and Alexa-647 
conjugated dextran (molecular weight 10,000) were obtained from Molecular 
Probes Invitrogen (Carlsbad, CA). LINCOplex Multiplex cytokine assay kits were 
purchased from Millipore (Temecula, CA). All antibodies used for flow cytometry 
CD11c, HLA-DR, CD40, CD86, CD83 and CD54 were obtained from BD 
Biosciences (San Jose, CA). The antibodies used for western blotting: CD83, 
CD86 and HLA-DR were obtained from Santa Cruz Biotechnology (Santa Cruz, 
CA). Chemokines CCL19 and CCL21 were obtained from PeproTech (Rocky Hill, 
NJ). 
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Table 1. Age and gender of donors used in the study 
Donor ID Age Gender 
13 31 Female 
14 24 Female 
A 61 Female 
B 26 Male 
C 20 Female 
D 21 Female 
E 21 Male 
F 21 Male 
G 42 Male 
H 28 Male 
I 59 Female 
J 50 Female 
K 42 Female 
 
Monocyte Isolation and culture  
In the human body DCs are generated via multiple pathways. They can be 
derived from CD34+ stem cell precursors or derived from blood monocytes (123). 
Monocyte-derived DCs generated from CD14 + cells obtained from peripheral 
blood are phenotypically and functionally similar to circulating DCs in the human 
body (47, 134). For the purposes of this study mdDCs provide a suitable in vitro 
model. CD14+ monocytes were isolated and cultured as described by Picki et al. 
(105). Leukocytes were extracted from buffy coats using Histopaque-1077. 
Monocytes expressing CD14 were positively selected with magnetic microbeads. 
 22
Purity (>90%) was verified by staining with anti-CD14 antibodies and analyzing 
by flow cytometry.  Cells were cultured at 1 × 106 cells/ml in complete RPMI (2% 
L-Glutamin,10% fetal bovine serum, 1% penicillin/streptomycin, 10mM Hepes, 
non-essential amino acids and 5mM sodium pyruvate) with 20 ng/ml each rh IL-4 
and GM-CSF for five days at 37°C in an atmosphere of 5% CO2 and 95% air, 
(supplementing at day three with fresh medium). On day 5, most cells express an 
immature DC phenotype expressing high CD11c, low CD40, CD86, CD83 and 
HLA-DR (113) (Figure 6). Mature DCs were induced by adding either LPS, Poly 
I:C or the cytokine TNF-α to the culture for 24hours (23). The mature phenotype 
was confirmed by surface marker expression (high CD11c, CD40, CD86, CD83 
and HLA-DR) measured by flow cytometry (Figure 6). DCs were identified by 
forward and side scatter morphology; those cells were gated and subjected to 
further analysis to quantify marker expression (Figure 5).  
 
                                 
Figure 5. Dendritic cell morphology gating based on forward and side scatter from flow cytometry 
after culture with GM-CSF and IL-4. 93.6 percent of the total events recorded were assumed to 
be DCs. 
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Figure 6. Surface marker expression on cultured immature and mature DCs. Cells display both 
immature and mature dendritic cell phenotype under the specified culture conditions. Surface 
marker expression determined by antibody staining of cell surface markers and flow cytometry 
analysis. The mature DCs express higher intensity surface marker expression than immature 
DCs. 
Immature DC Phenotype: 
CD11c+ 
HLA-DR+ (low) 
CD83- 
CD86+ (low) 
C40+ (low) 
 
Mature DC Phenotype: 
CD11c+ 
HLA-DR+ (high) 
CD83+ 
CD86+ (high)  
CD40+ (high) 
Un-stimulated Cells Stimulated Cells  
CD83 
CD86 
CD40 
CD11c 
HLA-DR 
Unstained cells 
Stained cells 
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T cell isolation and culture 
 CD4+ T cells were isolated from the non-CD14 expressing fraction remaining 
after monocyte depletion and cultured in complete RPMI. The untouched cells 
were negatively selected using magnetic beads (Miltenyi Biotec). 
 
Curcumin treatment and cell stimulation 
Curcumin, an ingredient of Indian curry powder, supplied as a powder (Sigma) is 
a polyphenolic compound insoluble in water. Dimethylsulfoxide (DSMO) is used 
as a solvent in this study and therefore used as a control. Curcumin was added 
to iDC culture (1 × 106 cells/ml and 3 ml/well in 6-well plates) at the indicated 
concentrations (20µM or 30µM in most experiments). Cultures were incubated for 
1 hour at 37°C in an atmosphere of 5% CO2 and 95% air after which a stimulant 
(LPS, Poly I:C or TNF-α) was added to the appropriate wells. Control wells 
received no stimulants. Cultures were incubated overnight at 37ºC and 5% CO2 
and 95% air. Curcumin toxicity was assessed by 7AAD incorporation and 
measured by flow cytometry. Cells were found to be 95% (± 0.06) viable after 24 
hours of culture under all conditions listed above. 
 
Cell viability by flow cytometry 
In order to assess the toxicity of curcumin in DC culture after a prolonged period, 
cell viability was assessed. Cells were collected and stained with 7-amino-
actinomycin D (7AAD), a nuclear dye, and analyzed by flow cytometry.7AAD is 
used to discriminate living cells from dead cells. Live cells with intact membranes 
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will exclude the dye, while damaged cells will allow the dye to enter the cell 
(114). The gating strategy was similar to that mentioned above (Figure 5). 
Measurements were taken at three time points using six concentrations of 
curcumin. The 30µM concentration is the highest at which viability does not fall 
below 90% after 12 hr culture (Figure 7). The 10µM concentration did not show 
significant changes in preliminary studies and so was not included in this work. 
Only the non-toxic 20µM or 30µM concentrations of curcumin were used for the 
experiments in this study. 
 
 
Figure 7. Dendritic cell viability measured by 7AAD staining and flow cytometry after 3 hrs, 12 hrs 
and 24 hrs of culture with curcumin at various concentrations. 
 
Surface marker analysis by flow cytometry 
Cells were collected, washed, re-suspended (1 × 106 cells/ml) and stained with 
fluorochrome-conjugated antibodies specific for DC surface markers CD11c, 
HLA-DR, CD40, CD86, CD83 and CD54. After staining, cells were washed and 
fixed with 4% paraformaldehyde (PFA) then re-suspended in staining buffer, 
protected from light and stored at 4°C until flow cytometry analysis. Cells were 
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analyzed using the Becton Dickenson (BD) Canto II with HTS sampler and BD 
FACSDiva™ software. Figures were generated using FlowJo software (Tree Star 
Inc.) 
 
Multiplex bead assay 
Cytokines produced by DCs in culture were measured by multiplex bead assay 
(Millipore). Culture supernatant was collected, centrifuged to remove any 
particulates and stored at -20°C. Cytokine levels measured from the supernatant 
using the LINCOplex human multiplex assay. Six cytokines (IL-12p70, IL-10, IL-
6, IL-8, TNFα and IFNγ) and two chemokines (IP-10 and fractalkine) were 
measured from DC supernatant using this method. Six cytokines (IL-2, IL-4, IL-6, 
IL-10, IL-13 and IFNγ) were measured from DC – TC co-culture supernatant after 
the mixed lymphocyte reaction (MLR). Assays were performed in duplicate 
according to the manufacturer’s instructions. In summary, samples were diluted 
with an equal volume of medium and 25µl aliquots were used per assay well. 
Culture medium was used as the blank for the assay. Samples were incubated 
with antibody coated capture beads for 1hr, wells were washed and the cocktail 
of biotin labeled anti-human cytokine antibodies were added to all wells. After a 
2hr incubation at room temperature streptavidin-phycoerythrin was added for 30 
minutes. Samples were analyzed using the Luminex 100 IS system and IS 2.3 
software (Luminex, Austin, TX). Data was generated as mean fluorescence 
intensity (MFI) for each cytokine. Standard curves were generated using 5 
parameter logistic regression based on known concentrations of the recombinant 
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cytokines provided by the manufacturer. This was used to calculate the 
concentration (pg/ml) for the samples that were assayed. 
 
Homotypic clustering 
Dendritic cell clustering is a hallmark of activated or mature cells. It allows cells to 
communicate with each other as well as responder cells such as T cells and B 
cells Cell to cell contact is critical for antigen presentation and the propagation of 
the adaptive immune response (31).  The size and density of the cluster may be 
indicative of the activation state of the cells. Strongly activated cells form larger 
and more dense clusters than weakly activated or immature cells. Clusters were 
observed by light microscopy at low power magnification (4x). Images were 
recorded using an Olympus digital camera. 
 
Western Blotting 
Cells were collected, washed and lysed using NP-40 lysis buffer containing 
protease and phosphatase inhibitors. Proteins were quantified using a BCA 
protein assay kit and 100µg loaded onto an SDS-PAGE gel. After 
electrophoresis, proteins were transferred onto a PVDF membrane by 
electrophoresis.  The membranes were blocked using 5% non-fat milk for 1 hr at 
room temperature and subsequently probed with the appropriate antibodies in 
5% bovine serum albumin (BSA) buffer overnight at 4°C. The membranes were 
washed and incubated with horseradish-peroxidase (HRP)-conjugated secondary 
antibodies. The bands were visualized by incubating the membranes in West 
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Pico chemiluminescent reagent (Thermo Scientific) for 5 minutes protected from 
light and exposing the membranes to x-ray film (Kodak). 
 
Endocytosis assay 
Immature DCs have the intrinsic ability to capture foreign materials by 
endocytosis. Stimulated or mature DCs do not possess this ability (113). This 
inherent property is used as a measure of DC maturity. Treated and stimulated 
cells were collected, washed and incubated with 1mg/ml (per 1×106 cells) Alexa 
647 conjugated dextran at either 4ºC or 37ºC for 1 hour. Cells were washed with 
cold PBS and either analyzed by flow cytometry or plated on gelatin coated cover 
slips and imaged by confocal microscopy. The change in mean fluorescence 
intensity (MFI) is calculated as the difference between the MFI of 37ºC and 4ºC 
cultures. 
 
Chemotaxis assay 
Another measure of DC function is its ability to migrate towards chemo-
attractants (81). Mature DCs are more motile than iDCs. Treated and stimulated 
cells were collected, counted and re-suspended at a concentration of 1 x 106 
cells/ml. 50µl of cell suspension was placed in the upper chambers of 5µm pore 
size polycarbonate filter inserts in a 96 well microchemotaxis plate (Chemicon). 
The lower chambers contained 40µl of either CCL19 or CCL21 in 150µl of 
medium. Control wells had medium only. Input wells (in triplicate) contained 1 x 
104 cells in the lower chambers without chemokines. Cells were incubated at 
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37ºC and 5% CO2/95% air overnight. Migration was stopped by the removal of 
the inserts. 1 x 104 polystyrene beads were added to each well (lower chamber) 
and analyzed by flow cytometry. The number of cells in each sample and input 
was calculated using the following equation: Number of cells/well = (number of 
cell events ÷ number of bead events) x 104. Input cells = average [number of 
input cells/well x 5 (dilution factor)]. The percentage migration for each sample 
(% input) is determined by the following equation: Percent migration = (migrating 
cells ÷ input cells) x 100. 
 
Mixed lymphocyte reaction 
Mature DCs are able to stimulate proliferation of allogeneic T cells and induce a 
helper response. In order to determine the effect of curcumin on DC function 
after stimulation, T cell proliferation and polarization was assayed using a mixed 
lymphocyte reaction. In order to measure proliferation, T cells were loaded with 
an intracellular dye carboxyfluoroscein succinimidyl ester (CFSE). CFSE 
passively diffuses into cells and reacts with amines in the cytoplasm forming 
highly fluorescent conjugates. As the cells divide the conjugates are distributed to 
the daughter cells. Fluorescence intensity was measured by flow cytometry, with 
each generation of cells emitting approximately half the fluorescence intensity of 
the parent. CFSE labeling of CD4+ T cells was carried out according to published 
procedures (108). Cells were suspended in 1ml PBS containing 5% (v/v) FBS. 
1.1µl of the CFSE stock (5µM) was diluted in 110µl of PBS and then quickly 
mixed with the cell suspension. After a 5 minute incubation at room temperature, 
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the reaction was stopped by adding ten volumes of room temperature PBS 
containing 5% (v/v) FBS and centrifuging at 300 × g for 5 minutes at 20ºC. Cells 
were washed twice and re-suspended in complete medium (1 × 106 cells/ml). The 
DC-T cell co-culture was set up at a ratio of 1:16. Curcumin treated and 
stimulated DCs were removed from culture and placed in 96 well plates in 
triplicate (6.25 × 103 cells in 100µl per well). 100µl of T cells were added to each 
well and cultures incubated at 37ºC and 5% CO2 /95% air for 5 days. 
Unstimulated T cells were used as the negative control, mitogen 
(phytohemagultinin: PHA at a concentration of 5µg/ml) stimulated T cells were 
used as the positive control. CFSE fluorescence intensity was measured by flow 
cytometry using the BD Canto II with HTS attachment and BD FACS Diva 
software. 
 
Immunofluorescence labeling 
Cells were collected, washed and fixed with 4% PFA.  For intracellular staining, 
cells were permeablized with CytoFix/CytoPerm solution (BD Pharmingen). Non-
specific antigens were blocked by using staining buffer containing FBS. The 
staining buffer also contained saponin (BD PermWash buffer) which maintains 
cell permeabilization. Cells were incubated with the appropriate antibodies, 
washed thoroughly and mounted in a glycerol-based mounting medium that 
contains DAPI. Slides were stored at 4ºC, protected from light until imaging. 
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Microscopy  
All bright field images were captured using the 4x objective of an Olympus IX71 
inverted fluorescent microscope with an attached DP70 camera. Fluorescent 
images were captured using either the 63x or the 40x objective of a Leica 
scanning confocal microscope. 
 
RNA extraction from human DCs 
Monocyte-derived DCs obtained from human peripheral blood were placed in 
experimental groups, treated with curcumin and stimulated with LPS (Figure 8). 
Total RNA was extracted from cells using the RNeasy isolation kit (Qiagen) as 
per the manufacturer’s instructions. RNA was quantified by optical density 
measurements and its purity and integrity determined by agarose gel 
electrophoresis of samples stored at room temperature and samples heated to 
42ºC for 1 hr and 70ºC for 10 minutes.  
 
Microarray  
All microarray experiments and analysis were carried out at the H. Lee Moffitt 
Cancer Center Microarray Core Lab.  Affymetrix HG U133 Plus 2 array 
GeneChips were used for the experiment. A separate chip was used for each of 
the four samples (Figure 8). Isolated RNA was biotinylated as described in the 
Affymetrix GeneChip Expression Analysis Manual (Affymetrix). 5µg total RNA 
was converted to double stranded DNA using 100pmol of an oligo-dT primer that 
contains a T7 promotor. The resulting cDNA was used in a transcription reaction 
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with biotinylated nucleotides. The product of this reaction was fragmented and 
hybridized to the GeneChips. After 16 hours of hybridization, the chip was 
washed and stained with streptavidin-phycoeryhtrin and then read using an 
Affymetrix GeneChip scanner. Data was processed using the GeneChip 
Operating Software (GCOS) Microarray Suite 5.0 (Affymetrix). Based on criteria 
set by Affymetrix GCOS software, only genes that are considered to be “present” 
will be used for further analysis. “Present” calls are made by comparing the 11 
perfect matches and mismatches for each probe set. The data generated was 
normalized to control genes and filtered by present and absent calls or by gene 
increase or decrease calls. Genes were annotated using software provided by 
the Microarray Core Facility. To identify cellular pathways affected by curcumin 
treatment and LPS stimulation, the data was examined using Ingenuity Systems 
Pathways Analysis 6.3 (Ingenuity Systems®, www.ingenuity.com) software which 
categorizes identified genes based on biological function and signaling pathways. 
Canonical Pathways Analysis identified the pathways from the Ingenuity 
Pathways Analysis library of canonical pathways that were most significant to the 
dataset.  The significance of the association between the dataset and the 
canonical pathway was measured in 2 ways: 1) A ratio of the number of genes 
from the dataset that map to the pathway divided by the total number of 
molecules that exist in the canonical pathway is displayed.  2) Fischer’s exact 
test was used to calculate a p-value determining the probability that the 
association between the genes in the dataset and the canonical pathway is 
explained by chance alone. 
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Figure 8. Experimental outline for microarray analysis 
 
Statistical analysis 
In this study a 4 x 3 factorial design was used. All values are reported as mean 
and standard error of the mean (SEM). Most data was transformed using a base 
10 logarithm to ensure normal distribution, with the exception of viability and 
proliferation values in which case the raw data was reported. All donors 
displayed similar trends in response to treatment and stimulation, however due to 
individual variation there were differences in the magnitude of the values. Paired 
t-tests (repeated measures) for planned comparisons were conducted. 
Significance was determined using a modified Bonferroni correction (55). Each 
test of significance was ranked and the range of observed p values were 
compared to critical alpha values a (a = alpha 0.05 divided by the number of 
Add DMSO for 12hr 
md-iDCs 
Add curcumin (20µM) 
dissolved in DMSO for 12hr 
Add curcumin (20µM) 
dissolved in DMSO for 1hr 
then add LPS for 11hrs 
Add DMSO for 1hr then 
add LPS for 11hrs 
RNA isolation 
Microarray 
Model Independent variable Dependent variable 
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planned comparisons). Values are presented as the average of six donors. Error 
bars represent SEM. All statistical calculations were performed using the 
Statistical Package for Social Sciences (SPSS version 15). Figures were 
generated using GraphPad Prisim (version 3.03). A concentration dependent 
reduction in values was observed in almost all cases. Though significance was 
calculated for only the 20µM concentrations, the change in values of the 30µM 
concentration compared with the control were therefore thought to be significant 
as well.  
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RESULTS  
Aim 1: Curcumin Prevents Dendritic Cell Maturation 
 
Curcumin Affects DC Morphology 
Dendritic cells have a characteristic morphology. They are slightly irregular 
in shape and have finger-like projections or dendrites that increase their surface 
area to maximize cell-cell contact. Curcumin appears to cause the cells to 
become more spherical and to lose their dendrites (Figure 9). This change is 
evident in both the absence and presence of LPS. Similar effects were noted for 
poly I:C and TNF-α stimulated cells (data not shown). 
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Figure 9. Curcumin affects cell morphology. Cells were cultured for 24hs with or without curcumin 
(20µM) and LPS (1µg/ml). Images were captured using an inverted light microscope with a 40x 
objective lens. Red arrows indicate cell dendrites. Images are from a single representative of 
eight donors. 
 
Curcumin Prevents Homotypic Cluster Formation  
Homotypic cluster formation correlates directly with phenotypic DC 
maturation. Stimulated or mature DCs will form clusters due to their increased 
marker expression and enhanced motility. In order to determine the effects of 
curcumin on DC clustering, cells were cultured in the presence of curcumin for 24 
hrs and then examined under an inverted light microscope using a low power 
objective (4x). Curcumin prevents DCs from forming large, dense clusters 
characteristic of mature DCs in response to stimulants such as LPS, poly I:C and 
TNF-α (Figure 10). This effect is concentration dependent as the 30µM 
DMSO LPS 
DMSO 
Cur 20µM 
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concentration abrogates cluster formation completely. There are some clusters 
formed in the experimental groups that received 20µM curcumin and were 
stimulated with poly I:C and TNF-α, but these were much smaller than those 
formed in the similarly stimulated control groups. The clusters formed in 
response to LPS were larger and more dense that those formed in response to 
poly I:C and TNF-α. 
 
Figure 10. Curcumin prevents homotypic clustering of stimulated DCs. Cells were cultured for 24 
hrs with or without curcumin (20µM or 30µM) and LPS, poly I:C or TNF-α added to the 
appropriate wells. Images were captured using an inverted light microscope with a 4x objective 
lens. Images are of a single representative of eight donors. 
No Stim LPS Poly I:C
DMSO 
Cur 20µM 
Cur 30µM  
TNF-α
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 Curcumin Reduces Surface Marker Expression  
Immunofluorescence labeling and flow cytometry was used to determine 
the effects of curcumin on surface marker expression. Cells were evaluated 
using two concentrations of curcumin (20µM and 30µM) and three immune 
stimulants (LPS, poly I:C and TNF-α). Data is reported either as percentage 
positive cells or mean fluorescence intensity (MFI) of all donors (n = 8). Table 2 
shows p values of significance for each experimental group assessed. A similar 
number of cells were stained for the surface markers CD11c, HLA-DR, CD83, 
CD86 and CD40 and analyzed in each experimental group. In order to determine 
the effects of surface marker expression on iDCs, cells were treated with 
curcumin for 24 hrs and no stimulant was introduced into culture. There was no 
significant change in surface marker expression for all donors (Figure 12). In 
figure 11 the unstimulated cells treated with 30µM curcumin show reduced CD86 
expression, this was only seen in this donor and not the trend across all donors. 
In the presence of all three stimulants, the cells that were treated with curcumin 
had reduced expression of CD83, CD86, CD54 and CD40 when compared to 
stimulated controls (Figures 11, 12). HLA-DR surface expression was not 
significantly affected by the 20µM concentration of curcumin; however the 30µM 
concentration of curcumin showed significant results (Figure 11). 
Immunofluorescece staining shows that curcumin-treated DCs retain some HLA-
DR in the cytoplasm (Figure 13a). Western blot shows curcumin-treated DCs 
have a lower level of expression of the antigen presenting molecules CD86, 
CD83 and HLA-DR (Figure 13b). All cells expressed high levels of CD11c, but by 
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measure of fluorescence intensity, the LPS and TNF-α stimulated cells treated 
with 30µM concentrations and the LPS stimulated cells 20µM showed 
significantly reduced expression of CD11c compared to stimulated controls. 
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Figure 11. Curcumin reduces dendritic cell surface marker expression in stimulated cells. Flow 
cytometry histograms are a single representative of 6 donors. The yellow-green line represents 
the unstained cells and used to designate the negative population.  
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Figure 12. Curcumin reduces dendritic cell surface marker fluorescence intensity in stimulated 
cells. The y-axis represents the average log10 mean fluorescence intensity (MFI) ± SEM for 8 
donors. * indicates significance by one-tailed t-test of planned comparisons p < critical alpha 
value.  
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Table 2. Significance of curcumin effects on surface marker expression (mean fluorescence 
intensity): Comparison of DMSO vs. Curcumin (Cur 20µM)  
 Mean (DMSO) 
Mean 
(Cur 20µM) 
Critical    
p value 
Observed 
p value Significance
No Stimulation      
    CD11c 4.830 ± 0.122 4.715 ± 0.134 0.0500 0.0051 Yes 
    HLA-DR 3.285 ± 0.350 3.279 ± 0.346 0.0500 0.4518 No 
    CD86 3.916 ± 0.120 4.010 ± 0.170 0.0500 0.0762 No 
    CD83 2.872 ± 0.235 2.730 ± 0.277 0.0500 0.0099 Yes 
    CD40 3.071 ± 0.488 3.132 ± 0.442 0.0500 0.0623 No 
    CD54 4.532 ± 0.190 4.377 ± 0.246 0.0500 0.0078 Yes 
LPS      
    CD11c 5.024 ± 0.042 4.842 ± 0.075 0.0085 0.0009 Yes 
    HLA-DR 3.544 ± 0195 3.542 ± 0.211 0.0170 0.1326 No 
    CD86 * 5.013 ±0.102 4.317 ± 0.145 0.0085 0.0000 Yes 
    CD83 3.868 ± 0.152 3.260 ± 0.208 0.0085 0.0001 Yes 
    CD40 3.793 ± 0.222 3.399 ± 0.336 0.0085 0.0005 Yes 
    CD54 * 5.052 ± 0.087 4.792 ± 0.107 0.0085 0.0000 Yes 
Poly I:C      
    CD11c 4.920 ± 0.076 4.621 ± 0.105 0.0170 0.0019 Yes 
    HLA-DR 3.412 ± 0.167 3.319 ± 0.197 0.0085 0.0013 Yes 
    CD86 * 4.644 ± 0.514 4.120 ± 0.446 0.0170 0.0000 Yes 
    CD83 3.542 ± 0.088 2.873 ± 0.111 0.0170 0.0004 Yes 
    CD40 3.854 ± 0.595 3.454 ± 0.589 0.0170 0.0011 Yes 
    CD54 4.659 ± 0.516 4.307 ± 0.615 0.0170 0.0011 Yes 
TNF-α      
    CD11c 4.926 ± 0.093 4.744 ± 0.076 0.0250 0.0022 Yes 
    HLA-DR 3.415 ± 0.198 3.409 ± 0.190 0.0250 0.4483 No 
    CD86 4.173 ± 0.523 4.006 ± 0.490 0.0250 0.0024 Yes 
    CD83 3.445 ± 0.106 2.995 ± 0.106 0.0250 0.0006 Yes 
    CD40 4.463 ± 0.633 4.282 ± 0.569 0.0250 0.0188 Yes 
    CD54 3.884 ± 0.799 3.679 ± 0.819 0.0250 0.0033 Yes 
* observed p values were less than 0.0001
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Figure 13. Curcumin reduces the expression of the antigen presentation molecules. 
Immunofluorescence labeling of fixed and permeabilized DCs (A) and western blot of whole cell 
lysate (B) showing reduced expression of marker expression in the presence of curcumin and 
LPS.  
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Curcumin Reduces Cytokine Production 
 Cytokine production by dendritic cells is indicative of maturation. 
Cytokines produced will begin the cascade of immune reaction and induce cell – 
cell interactions which initiate the adaptive response. In order to assess the 
effects of curcumin on cytokine production, iDCs were treated with two 
concentrations of curcumin and stimulated with either LPS or poly I:C. Culture 
supernatants were collected and analyzed by multiplex bead assay. IFNγ, IL-
12p70, the immunomodulatory cytokine IL-10 as well as pro-inflammatory 
cytokines IL-6, IL-8 and TNF-α were measured. The assay was carried out in 
duplicate and the average of 6 donors is represented in figure 14. Due to the 
innate variations in donor response to the stimulants, the data are averaged and 
represented as log10 concentration. Table 3 shows the p value significance for 
the curcumin effects noted in this assay. Table 4 shows the p value significance 
of the stimulant effects. Characteristically low levels of all cytokines were 
produced by non-stimulated cells. These levels were not affected by curcumin at 
either concentration. Stimulation with LPS and poly I:C resulted in substantial 
production of all cytokines. IL-10, IL-6 and IL-12p70 were significantly reduced in 
the curcumin treated cells stimulated with LPS and poly I:C in a concentration 
dependent manor. These levels were more or less reduced to the levels of the 
iDC cells that received no stimulation (Figure 14). In cells stimulated with LPS, 
higher levels of IL-8 were produced than the poly I:C stimulated groups. Some 
values were outside of the dynamic range of the assay. The 20µM curcumin 
concentration significantly increased IL-8 production in poly I:C stimulated cells 
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above the stimulated controls. Due to the fact that the LPS-stimulated 20µM 
curcumin treated cells were out of the range of the assay, the curcumin effects 
were not significant. The 30µM concentration did not reduce levels below the 
untreated control in response to either stimulant. There was a significant increase 
in IL-8 levels however in the unstimulated control group treated with curcumin 
(20µM). The level of IFNγ produced in this assay was minimal. In LPS-stimulated 
cells, curcumin caused a significant reduction in the amount of this cytokine that 
was produced. No significant reduction was observed in the poly I:C stimulated 
group. Stimulated DCs showed significantly reduced TNF-α levels in when 
curcumin was present. Though this reduction was concentration dependent, 
unlike with the other cytokines, the TNF-α levels were not reduced to that of the 
unstimulated controls (Figure 14). 
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Figure 14. Curcumin reduces cytokine production by human DCs in response to stimulants. Cells 
were cultured in the presence of curcumin (20µM and 30µM) and stimulated with either LPS or 
poly I:C. Data is represented as log (base 10) concentration and the average of 6 donors. Error 
bars are SEM and * indicates significance (p < critical alpha) 
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Table 3. Significance of curcumin effects on cytokine production: Comparison of DMSO vs. Cur 
20µM 
 Mean (DMSO) 
Mean 
(Cur 20µM) Critical p Observed p Significant 
      
No Stimulation      
    IL-10 1.196 ± 0.454 0.977 ± 0.459 0.025 0.003 Yes 
    IL-12p70 0.477 ± 0.000 0.477 ± 0.000 - - - 
    IL-6 1.194 ± 0.676 1.099 ± 0.831 0.05 0.199 Yes 
    IL-8 2.022 ± 0.428 2.553 ± 0.899 0.025 0.0078 Yes 
    TNF-α 1.234 ± 0.113 0.869 ± 0.548 0.025 0.0665 No 
    IFNγ 0.627 ± 0.423 0.477 ± 0.000 0.05 0.1753 No 
      
LPS      
    IL-10 3.453 ± 0.825 2.078 ± 1.011 0.017 0.0005 Yes 
    IL-12p70 2.626 ± 0.983 0.964 ± 0.596 0.025 0.002 Yes 
    IL-6 4.132 ± 0.257 3.372 ± 0.926 0.025 0.009 Yes 
    IL-8 4.162 ± 0.306 4.314 ± 0.022 0.05 0.097 No 
    TNF-α 4.157 ± 0.388 3.623 ± 0.398 0.017 0.0065 Yes 
    IFNγ 1.557 ± 0.764 0.832 ± 0.612 0.017 0.0074 Yes 
      
Poly I:C      
    IL-10 1.705 ± 0.394 1.151 ± 0.585 0.05 0.001 Yes 
    IL-12p70 2.467 ± 1.296 0.865 ± 0.809 0.05 0.003 Yes 
    IL-6 3.309 ± 0.497 2.285 ± 0.808 0.017 0.001 Yes 
    IL-8 3.309 ± 0.497 3.630 ± 0.282 0.017 0.0007 Yes 
    TNF-α 2.839 ± 0.918 2.362 ± 0.702 0.05 0.0145 Yes 
    IFNγ 0.780 ± 0.424 0.557 ± 0.225 0.025 0.1376 No 
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Table 4. Significance of stimulant effects: Comparison DMSO (No stim) vs. Stimulant (Stim) 
 Mean (No Stim) 
Mean 
(Stim) 
Critical     
p value 
Observed  
p value Significance
      
LPS*      
    IL-10 1.196 ± 0.454 3.453 ± 0.825 0.025 0.0000 Yes 
    IL-12p70 0.477 ± 0.00 2.626 ± 0.983 0.025 0.0000 Yes 
    IL-6 1.194 ± 0.676 4.132 ± 0.257 0.025 0.0000 Yes 
    IL-8 2.022 ± 0.428 4.162 ± 0.306 0.025 0.0000 Yes 
    TNFα 1.234 ± 0.113 4.157 ± 0.388 0.025 0.0000 Yes 
    IFNγ 0.627 ± 0.423 1.557 ± 0.764 0.025 0.0210 Yes 
      
Poly I:C      
    IL-10 1.196 ± 0.454 1.705 ± 0.394 0.05 0.0010 Yes 
    IL-12p70 0.477 ± 0.00 2.467 ± 1.296 0.05 0.0015 Yes 
    IL-6 1.194 ± 0.676 3.309 ± 0.497 0.05 0.0005 Yes 
    IL-8 2.022 ± 0.428 3.309 ± 0.497 0.05 0.0035 Yes 
    TNFα 1.234 ± 0.113 2.839 ± 0.918 0.05 0.0010 Yes 
    IFNγ 0.627 ± 0.423 0.780 ± 0.424 0.05 0.2719 No 
* Observed p values were less than 0.0001 
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Aim 2: Curcumin Prevents Dendritic Cell Function 
  
Curcumin Reduces Endocytosis  
Endocytosis is a feature of immature dendritic cells which are usually 
found in the periphery. Maturing migrating DCs lose their ability to edocytose. 
Therefore, the test of endocytic capacity is thought of as the gold standard in 
assessing DC maturity as a measure of function. In order to assess the effects of 
curcumin on iDC endocytosis, cells were cultured in the presence of curcumin for 
24hrs and then cultured with fluorescently labeled dextran (MW 10,000). Dextran 
uptake was measured by flow cytometry and confocal microscopy. Data is 
represented as the average change in mean fluorescence intensity (MFI) of six 
donors (Figure 15b). Confocal microscope imaging of a representative donor is 
shown in figure 15a. The significance of the effects of curcumin are shown in 
table 4 and the significance of stimulant effects are shown in table 5.  
Curcumin prevents iDCs from taking up dextran in a concentration 
dependent manner (Figure 15b). In the curcumin treated cells, dextran 
accumulates along the cell membrane and not throughout the cytoplasm as in 
the untreated control (Figure 15a).  LPS stimulated cells show characteristically 
reduced dextran uptake. The level of endocytosis for both LPS and poly I:C 
stimulated DCs were significantly reduced when compared to the unstimulated 
control (open bars in figure 15b). Pre-treated stimulated DCs show dextran 
uptake similar to that of the unstimulated pre-treated controls (black and hatched 
bars in Figure 15b). Similar to curcumin treated DCs, LPS stimulated DCs show 
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dextran accumulated along the cell membrane and not throughout the cytoplasm 
(Figure 15a). There was no significant difference between curcumin-treated and 
untreated DCs in the LPS and poly I:C treated experimental groups (Table 5). 
 
 
 
Figure 15. Curcumin reduces endocytosis in human dendritic cells. Confocal microscopy image 
(a) and change in mean fluorescence intensity (MFI) as measured by flow cytometry (B). 
Confocal images were captured using a 64x objective lens. Change in MFI was calculated by 
subtracting the MFI at 4ºC from the MFI at 37ºC. * indicates significant curcumin effects p < 0.05; 
† indicates significant stimulant effects p < 0.05.  
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Table 5. Significance of curcumin effects on endocytosis: Comparison of DMSO vs. Cur 20µM 
 Mean (DMSO) 
Mean 
(Cur 20µM) 
Critical    
p value 
Observed  
p value Significance
      
No Stim 23,729 ± 6196 13,596 ± 6353 0.017 0.0126 Yes 
LPS 12,726 ± 12,237 9,850 ± 8,543 0.025 0.1165 No 
Poly I:C  14,242 ± 9,198 12,964 ± 6,060 0.050 0.2960 No 
 
 
Table 6. Significance of the effects of stimulants on endocytosis: Comparison of DMSO (No Stim) 
vs. Stimulant (Stim) 
 Mean (No Stim) 
Mean 
(Stim) 
Critical    
p value 
Observed  
p value Significance
      
LPS 23,729 ± 6196 12,726 ± 12,237 0.050 0.0418 Yes 
Poly I:C  23,729 ± 6196 14,242 ± 9,198 0.050 0.0382 Yes 
 
 
Curcumin Reduces Chemokine Secretion  
 Chemokines are cytokines that induce cellular migration. Two key 
cytokines produced by DCs to attract inflammatory cells that are fractalkine 
(CX3CL1) and IP-10 (CXCL10). The supernatant of DC experimental cultures 
were analyzed for these chemokines by multiplex bead assay. Data are reported 
as the average log10 transformed concentration of four donors. The significance 
of the curcumin effects are shown in table 7. A lower concentration of curcumin 
(20µM) was used in this experiment, since for previous experiments the changes 
at this concentration were found to be significant. LPS was the only stimulant 
used as curcumin effects do not seem to depend on the stimulant used. 
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Curcumin reduces the levels of IP-10 and fractalkine produced in LPS-stimulated 
DCs (Figure 16). The reduction in IP-10 production was found to be significant, 
however, due to the low levels of fractalkine produced, the reduction was not 
found to be significant (Table 7). 
 
 
Figure 16. Curcumin reduces chemokine production by dendritic cells. Error bars represent SEM 
and * indicates p values < critical value. 
 
Table 7. Significance of curcumin effects on chemokine production: Comparison DMSO vs. Cur 
20µM 
 Mean (DMSO) 
Mean 
(Cur 20µM) Critical p Observed p Significant 
      
No Stimulation      
    IP-10 1.588 ± 0.769 1.144 ± 0.726 0.05 0.0828 No 
    Fractalkine 0.486 ± 0.015 0.382 ± 0.166 0.05 0.2113 No 
      
LPS      
    IP-10 4.278 ± 0.036 3.008 ± 0.705 0.025 0.0009 Yes 
    Fractalkine 0.980 ± 0.456 0.486 ± 0.015 0.025 0.0970 No 
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Curcumin Prevents DC Chemotaxis  
DC chemotaxis is a characteristic function of mature DCs. After they 
acquire antigen they migrate towards lymphoid organs to stimulate T 
lymphocytes. In order to assess the effects of curcumin on DC chemotaxis, 
treated and stimulated cells were placed in a chemotaxis chamber and allowed to 
migrate towards chemo-attractants CCL19 and CCL21. Data is reported as the 
average percent cell migration of two donors. The significance of the effects of 
curcumin are shown in table 8. The samples were normalized to the percentage 
of cells migrating towards medium only. Curcumin treated cells are unable to 
migrate towards the chemo-attractants CCL19 and CCL21 in response to LPS 
(Figure 17). The chemokine receptor CCR7, expressed on the surface of DC 
binds both the CCL21 and CCL19 ligands. The expression of CCR7 is not 
affected by curcumin (Figure 18). CCR7 expression on DCs was evaluated by 
surface marker immunofluorescence staining followed by flow cytometry (Figure 
18a,b) and by western blot of whole cell lysate (Figure 18c).  
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Figure 17. Curcumin prevents chemotaxis of dendritic cells in response to LPS. Cell migration 
was normalized using percent cell migration towards culture medium. Error bars represent SEM 
and * indicates p values < critical value. CCL21 – chemokine ligand 21 or exodus-2; CCL19 – chemokine ligand 
19 or macrophage inflammatory protien-3-beta (MIP-3β) 
 
 
Table 8. Significance of curcumin on dendritic cell chemotaxis: Comparison of DMSO vs. Cur 
20µM 
 Mean (DMSO) 
Mean 
(Cur 20µM) 
Critical    
p value 
Observed  
p value Significance
      
CCL21      
    No Stim 0.599 ± 0.765 0.160 ± 0.089 0.050 0.2999 No 
    LPS 25.219 ± 1.457 0.176 ± 0.083 0.025 0.0123 Yes 
      
CCL19      
    No Stim 0.780 ± 0.052 0.117 ± 0.087 0.025 0.0120 Yes 
    LPS 22.431 ± 3.225 0.319 ± 0.439 0.050 0.0371 Yes 
 
DMSO
Cur 20µMCCL21
0
10
20
30
40
50
Pe
rc
en
t C
el
l M
ig
ra
tio
n
CCL19
0
10
20
30
40
50
Pe
rc
en
t C
el
l M
ig
ra
tio
n
No Stim LPS No Stim LPS 
* * *
 55
 
 
Figure 18. Expression of the chemokine receptor CCR7 is not affected by curcumin. CCR7 
expression is determined both on the cell surface by immunofluorescence labeling and flow 
cytometry (a and b) and intracellularly by western blot of whole cell lysate of a representative 
donor (c). Histograms shown are from a single donor (a) and the bar chart shows the average 
mean fluorescence intensity (MFI) of four donors with error bars representing SEM (b). 
CCR7 – chemokine receptor 7; GAPDH – gylceraldehyde 3- phosphate dehydrogenase. 
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Curcumin Reduces DC-induced T Cell Proliferation in an Allogeneic Mixed 
Lymphocyte Reaction 
The mixed lymphocyte reaction can be used as a measure of DC 
maturation. Although iDCs can weakly stimulate T cell proliferation, mDCs initiate 
a more robust proliferation of the T cell population in a co-culture. In order to 
study the effects of curcumin in this process, iDCs were treated with curcumin, 
stimulated with either LPS or poly I:C and then co-cultured with allogeneic CD4+ 
T helper cells from mismatched donors. The T cells were pre-loaded with CFSE, 
an intracellular dye and proliferation was assessed after 5 days of co-culture by 
flow cytometry. Flow cytometry data is represented as either the average mean 
fluorescence intensity of six donors or of a representative donor. The significance 
of curcumin effects and stimulant effects on the experimental populations are 
shown in tables 8 and 9 respectively. For the flow cytometry analysis, gates were 
set based on side scatter vs. forward scatter morphology (figure 19a) and those 
cells were evaluated for CFSE expression. Proliferated cells have lower 
fluorescence intensity of CFSE than unproliferated cells. Mature DCs induce 
significantly higher proliferation by CD4+ T cells than iDCs (Figure 20). Though 
iDCs induce some proliferation in the T helper cell population, curcumin 
significantly impairs this ability as the number of proliferated cells is reduced from 
25.28 (± 10.84) % to 4.83 (± 4.20) % on average. Even in the presence of the 
stimulants LPS or poly I:C curcumin-treated DCS are unable to induce 
proliferation of T helper cells at levels greater than 6.03 (± 3.50) % (Figure 19).  
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Figure 19. Curcumin reduces DCs ability to induce proliferation in allogeneic CD4+ helper T cells 
in a MLR. Data is representative of six donors. The gating strategy is shown in panel (a) and the 
histograms of gated cell proliferation based on CFSE fluorescence is show in panel (b). CFSE – 
carboxyfluorescein succinimdyl ester; MLR – mixed lymphocyte reaction. 
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Figure 20. Curcumin-treated DCs show reduced CD4+ T cell proliferation in allogeneic MLR. Data 
represents the average of six donors. 
 
Table 9. Significance of curcumin effects on inducing proliferation of CD4+ T cells: Comparison of 
DMSO vs. Cur 20µM 
 Mean (DMSO) 
Mean 
(Cur 20µM) 
Critical    
p value 
Observed  
p value Significance
      
No Stim 25.275 ± 10.838 4.825 ± 4.195 0.050 0.0215 Yes 
LPS 38.750 ± 10.376 4.700 ± 1.337 0.017 0.0040 Yes 
Poly I:C  36.900 ± 13.422 6.025 ± 3.491 0.025 0.0055 Yes 
 
 
Table 10. Significance of stimulated DCS inducing T cell proliferation: Comparison DMSO (No 
stim) vs. Stimulated cells (Stim) 
 Mean (No Stim) 
Mean 
(Stim) 
Critical    
p value 
Observed  
p value Significance
      
LPS 25.275 ± 10.838 38.750 ± 10.376 0.05 0.0045 Yes 
Poly I:C  25.275 ± 10.838 36.900 ± 13.422 0.05 0.0570 No 
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Curcumin Induces a CD4+ CD25+ T Regulatory Cell Population 
 Mature DCs will induce T helper cell differentiation. In order to assess the 
effects of curcumin on the phenotype of proliferated T cells in co-culture, cells 
were immunoflourescently labeled for FoxP3 and CD25. Proliferated T cells were 
gated and only that population was analyzed for surface marker expression 
(Figure 22a). Curcumin-treated DCs, both stimulated and unstimulated induce a 
CD4+ CD25+ FoxP3+ population from the proliferated T cell population (Figures 
21 and 22b). Culture supernatant was also assessed for T helper cytokines IL-2, 
Il-4, IL-5, IL-10, IL-13 and IFNγ. Data is reported as average log10 concentration 
of four donors. Curcumin-treated DCs induced significantly lower cytokine 
production from the T cells in co-culture.  
 
 
 
 
 
 
 
 
 
 
Figure 21. Curcumin-treated DCs induce regulatory T cells in MLR. Data represents the average 
percentage of FoxP3+ CD25+ T cells of four donors. Only the proliferated cell population was 
analyzed. Error bars represent the SEM. 
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Figure 22. Curcumin induces CD4+ CD25+ FoxP3+ regulatory T cells. After 5 days of co-culture 
with curcumin-treated and stimulated DCs in an allogeneic MLR, T cells were immuno-
fluorescently labeled and analyzed by flow cytometry. The gating strategy is outlined in panel (a); 
cells are gated based on morphology and then proliferated T cells are gated and analyzed for 
FoxP3 and CD25 expression. The numbers are the relative percentages of proliferated cells (b)
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Figure 23. Curcumin reduces T helper cytokine production after five days of co-culture in 
allogeneic MLR with DCs. Cytokines were measured from the supernatant after T cell co-culture 
with curcumin-treated, stimulated DCs. Data is reported as average log10 concentration ± SEM. 
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Table 11. Significance of the effects of curcumin on DC-induced T cell cytokine production 
 
 
Mean 
(DMSO) 
Mean 
(Cur 20µM) Critical p Observed p Significant 
      
No Stimulation      
    IL-2 1.270 ±0.201 0.477 ± 0.000 0.017 0.0021 Yes 
    IL-10 2.941 ± 0.226 0.925 ± 0.383 0.017 0.0013 Yes 
    IL-4 1.886 ± 0.217 1.425 ± 0.146 0.050 0.0320 Yes 
    IL-13 2.463 ± 0.433 0.843 ± 0.486 0.025 0.0075 Yes 
    IL-5 1.485 ± 0.286 0.477 ± 0.000 0.025 0.0029 Yes 
    IFNγ 2.213 ± 0.142 0944 ± 0.464 0.025 0.0027 Yes 
      
LPS      
    IL-2 1.777 ± 0.350 0.477 ± 0.000 0.025 0.0025 Yes 
    IL-10 3.100 ± 0.279 1.213 ± 0.517 0.025 0.0034 Yes 
    IL-4 2.054 ± 0.251 1.452 ± 0.142 0.017 0.0061 Yes 
    IL-13 2.792 ± 0.407 0.826 ± 0.394 0.017 0.0013 Yes 
    IL-5 1.979 ± 0.319 0.477 ± 0.000 0.017 0.0013 Yes 
    IFNγ 2.722 ± 0.230 0.933 ±0.121 0.017 0.0001 Yes 
      
Poly I:C      
    IL-2 1.516 ± 0.715 0.477 ± 0.000 0.050 0.0311 Yes 
    IL-10 2.571 ± 1.003 1.403 ± 0.440 0.050 0.0154 Yes 
    IL-4 1.904 ± 0.343 1.458 ± 0.136 0.025 0.0219 Yes 
    IL-13 2.230 ± 1.185 0.815 ± 0.394 0.050 0.0390 Yes 
    IL-5 1.506 ± 0.705 0.477 ± 0.000 0.050 0.0308 Yes 
    IFNγ 2.086 ± 0.926 0.921 ± 0.268 0.050 0.0408 Yes 
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Aim 3: Curcumin Modulates the Actin Cytoskeleton 
 
Microarray Analysis of Total RNA Reveals the Effects of Curcumin on Gene 
Expression in Dendritic Cells 
 Curcumin has anti-inflammatory, anti-oxidant and anti-viral properties. It is 
reasonable to speculate that changes in gene expression as well as protein 
expression are in part responsible for these properties. In order to assess the 
effect of curcumin on human dendritic cells, DCs were cultured with curcumin 
and then stimulated with LPS. Total RNA was analyzed using an Affymetrix HG 
U133 plus 2 genome array. Ingenuity pathways analysis (IPA) software was used 
to identify pathways that may be affected. Table 12 shows some pathways that 
were most significantly affected by curcumin treatment as identified by IPA 
software. Many of the pathways affected are associated with cell structure, 
motility and function. These pathways also have many of the same molecules in 
common. Upon closer inspection of the actin cytoskeleton pathway, though many 
genes are unaffected, there are some genes that show an increase or decrease 
in expression in response to curcumin-treated and stimulated cells when 
compared to LPS-stimulated cells (Table 13). Of interest are those genes that 
are down-regulated in curcumin-treated and stimulated cells such as nexilin 
which decreased 129 fold. A few GTPases and Rho family members were down-
regulated along with WASP interacting protein, plexin and a tubulin-specific 
chaperone. 
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Table 12. Some pathways affected by curcumin as determined by Ingenuity pathways analysis 
software. 
 Pathway -Log(P-value) 
 Axonal Guidance Signaling 0.01540 
 Purine Metabolism 0.01220 
 Glucocorticoid Receptor Signaling 0.01060 
 Xenobiotic Metabolism Signaling 0.00966 
 Huntington's Disease Signaling 0.00904 
 Actin Cytoskeleton Signaling 0.00868 
 G-Protein Coupled Receptor Signaling 0.00828 
 Integrin Signaling 0.00810 
 Protein Ubiquitination Pathway 0.00801 
 Leukocyte Extravasation Signaling 0.00779 
 LPS/IL-1 Mediated Inhibition of RXR Function 0.00766 
 ERK/MAPK Signaling 0.00766 
 NRF2-mediated Oxidative Stress Response 0.00735 
 Calcium Signaling 0.00735 
 Ephrin Receptor Signaling 0.00726 
 Acute Phase Response Signaling 0.00717 
 RAR Activation 0.00703 
 Wnt/β2-catenin Signaling 0.00681 
 cAMP-mediated Signaling 0.00663 
 PPARα/RXRα Activation 0.00659 
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Table 13. Actin cytoskeleton pathway genes affected by curcumin. 
Gene 
Symbol Gene description 
Fold change 
Cur 20µM + LPS 
vs LPS 
RHOBTB1 Rho-related BTB domain containing 1 11.761 
PLEC1 plectin 1, intermediate filament binding protein 5.332 
SVIL supervillin 4.815 
FGD6 FYVE, RhoGEF and PH domain containing 6 4.408 
MAP7 microtubule-associated protein 7 4.292 
CDC42EP3 CDC42 effector protein 3 4.081 
ARHGDIB Rho GDP dissociation inhibitor (GDI) beta 3.836 
RHOBTB2 Rho-related BTB domain containing 2 3.727 
SPTAN1 spectrin, alpha, non-erythrocytic 1 (alpha-fodrin) 3.4278 
SPTBN1 spectrin, beta, non-erythrocytic 1 2.3971 
RASA4 RAS p21 protein activator 4 1.994 
PAK1 p21/Cdc42/Rac1-activated kinase 1 1.172 
VCL vinculin 1.155 
FGD4 FYVE, RhoGEF and PH domain containing 4 -1.074 
CDC42SE1 Cdc42 small effector 1 -1.408 
RND3 Rho family GTPase 3 -1.442 
PHACTR2 phosphatase and actin regulator 2 -1.454 
PHACTR4 phosphatase and actin regulator 4 -1.582 
RAB12 RAB12, member RAS oncogene family -1.659 
MYOZ3 myozenin 3 -1.687 
ARHGAP25 Rho GTPase activating protein 25 -1.835 
RAB30 RAB30, member RAS oncogene family -1.888 
TBCD tubulin-specific chaperone d -2.161 
WASPIP Wiskott-Aldrich syndrome protein interacting protein -2.214 
MASTL microtubule associated  serine/threonine kinase-like -2.885 
PLXNA1 plexin A1 -3.426 
ARHGAP25 Rho GTPase activating protein 25 -4.224 
RHOH ras homolog gene family, member H -4.681 
SCIN scinderin -4.695 
RABGAP1L RAB GTPase activating protein 1-like -4.976 
NEXN nexilin (F-actin binding protein) -129.149 
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Curcumin Alters the Actin Cytoskeleton in Human DCs 
The actin cytoskeleton of DCs is responsible for its shape and function. 
We hypothesize that curcumin can alter the conformation of the cytoskeleton and 
so provide a mechanism for its observed anti-inflammatory effects. Fluorescently 
labeled phalloidin was used to visualize actin in this experiment. In order to 
assess the effect of curcumin on the cell architecture, DCs were treated with 
curcumin, washed, fixed with 4% paraformaldehyde and stained with Alexa 555-
phalloidin in suspension. The cell nucleus was visualized using mounting 
medium containing the nuclear dye 4', 6-diamidino-2-phenylindole (DAPI). 
Images were captured using a confocal microscope and representative z slices 
are shown in figure 24. Cytochalasin B (CytoB) prevents actin polymer elongation 
and causes cells to become more rounded. It was used as a control in this study. 
Increasing concentrations of curcumin causes DCs to become more rounded and 
less filamentous. The rounding and loss of protrusions is similar to what was 
observed in the presence of the actin inhibitor CytoB (Figure 25). 
The actin cytoskeleton plays an important role in cell adhesion and 
motility. In order to assess curcumin effects, iDCs were allowed to adhere to 
gelatin coated cover slips for 2 hrs at 37ºC (5%CO2 and 95% air). iDCs were 
either treated with curcumin or stimulated. Actin accumulates at podosomes 
towards the leading edge of the iDCs (Figure 24, left). Curcumin-treated cells 
show podosome formation, but the cells are not elongated (Figure 24, center). 
Maturing LPS-stimulated DCs do not show podosomes but rather stress fiber 
formation (Figure 24, right). In order to assess the effect of curcumin on cell 
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attachment, DCs are treated with curcumin and stimulated before they are 
allowed to attach to poly L-lysine coated slides. Curcumin-treated DCs have a 
rounded morphology and do not adhere tightly to the substrate (Figure 26, 
center). iDCs and LPS-stimulated DCs adhere and are polarized with leading-
edge lamellapodia (Figure 26, left). DCs treated with an actin inhibitor, 
cytochalasin B, were rounded and loosely adherent (Figure 26, right). The Rho 
GTPases play an essential role in cellular organization. Curcumin reduces the 
activity of Rac1 and Cdc42 GTPases evidenced by western blotting of whole cell 
lysate using phospho-antibodies. The expression of Cdc42 was not affected 
(Figure 27). 
 
 
Figure 24. Curcumin interferes with DC motility and attachment. DCs were allowed to adhere to 
gelatin for 2 hrs at 37ºC, 5% CO2 and 95% air.  Curcumin and LPS were added to appropriate 
wells. After 1hour, cells were fixed with 4% paraformaldehyde and stained with phalloidin to 
visualize f-actin. Images were captured with a confocal microscope using a 63x objective lens. 
Red – Alexa 555-phalloidin; blue – 4', 6-diamidino-2-phenylindole (DAPI); green – curcumin 
fluorescing in FITC channel.
DMSO Cur 20µM LPS 
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Figure 25. Curcumin changes DC morphology in a concentration dependent manor. DCS were 
fixed, stained and imaged in suspension to maintain their three-dimensional shape. Curcumin 
inhibits actin similar to cytochalasin B. The nucleus if the cell is represented by the blue color 4', 
6-diamidino-2-phenylindole (DAPI), the actin is stained red (Alexa 555), curcumin fluoresces at 
about 435nm and is detected in the FITC channel. This accounts for the increasing green color in 
the cytoplasm of the cells as the concentration of curcumin increases. iDC – immature DC 
(untreated); DMSO – dimethyl sulfoxide; Cytochalasin B – an actin inhibitor; Cur - curcumin 
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Figure 26. Curcumin affects DC adhesion. DCs were cultured with curcumin and stimulated with 
LPS overnight, washed and allowed to adhere to poly L-lysine coated slides for 2 hrs. Cells were 
fixed with 4% paraformaldehyde and stained for actin (Alexa 555-phalloidin). Images were 
captured with a confocal microscope using a 40x objective lens.  
 
 
 
Figure 27. Curcumin reduces the activity of the Rac1/Cdc42 kinases. Western blots from whole 
cell lysate of curcumin-treated stimulated DCs.
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Curcumin-Induced Reduction in Endocytosis May be Due to Actin Inhibition.  
The actin cytoskeleton plays a key role in iDC endocytosis. In order to 
assess whether the curcumin-induced reduction in phagocytosis is mediated by 
actin inhibition, a known actin inhibitor, cytoB, was used as a control. CytoB-
treated cells showed a similar reduction in phagocytosis to curcumin treated cells 
(Figure 28). 
 
 
 
Figure 28. Disruption of the actin cytoskeleton causes reduced endocytosis in immature DCs. 
DCs cultured with curcumin for 24hrs and then endocytosis assay was performed.  
 
 
 
DMSO Cur 20 µM CB LPS Cur 20+LPS
0
25000
50000
75000
C
ha
ng
e 
M
FI
 
 71
 
 
 
DISCUSSION 
 
This is the first study to examine the effects of curcumin on human 
dendritic cells in vitro. Donors for the study were selected at random and 
supplied by Florida Blood Services, St. Petersburg, Florida. The concentrations 
of curcumin used were based on those previously found efficacious in the 
literature and confirmed not to be toxic to the cells by viability assays. All cultures 
remained more than 90% viable up to 24hrs after curcumin addition. The 
pharmacokinetics and pharmacodymanics of curcumin have been more 
extensively studied in rodents than in humans (120). From the limited human 
data available, the low bioavailability of curcumin limits its clinical usefulness 
when administered orally. High doses can be administered without adverse 
effects but the systemic distribution may not be sufficient to exert 
pharmacological activity. Combining curcumin with other compounds, or using 
drug delivery systems such as  liposomes and nanoparticles provide an 
alternative approach to overcome these issues (20, 122, 142). The 
immunostimulants lipopolysacchaide (LPS) and polyinosinic:polycytidylic acid 
(poly I:C) were used in this study to independently stimulate DC activation. LPS 
via the toll-like receptor 4 (TLR4) pathway and poly I:C mimics viral infections 
through TLR3. TNF-α signals through its receptor, TNF-R, which is a TLR-
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independent pathway. These compounds were chosen to ensure the 
immunostimulatory effects were not pathway specific or TLR dependent.  
The inhibition of transcription factors NFκB and AP-1 and other cell 
signaling pathways by curcumin explains some of the observations made in this 
study, but curcumin may be targeting other essential cellular pathways as well. 
The observations of this study suggest curcumin functions as an inhibitor of actin 
signaling. Since f-actin reorganization is responsible for dendritic cell maturation 
and function, its inhibition may be the mechanism by which curcumin prevents 
DC response to stimulants.  Elucidation of the underlying mechanism of curcumin 
immunosuppression could lead to clinical applications of this novel anti-
inflammatory agent. 
DCs aggregate in clusters in response to stimuli as a visual sign of 
maturation (31). Cluster formation correlates with increased CD86, CD54 and 
CD80 expression. Here we show curcumin impairs homotypic DC cluster 
formation in response to LPS poly I:C and TNF-α in a concentration-dependent 
manner. Adhesion molecules such as ICAM-1 (CD54) are important in cellular 
interactions and in generating T cell response. Murine antigen presenting cells 
(APCs) deficient in ICAM-1 have an impaired ability to induce T cell responses 
(41, 126). CD11c, a member of the integrin family of proteins, is also important 
for cell attachment and found in high levels on DCs. Curcumin significantly 
reduces expression of both markers on the DC surface. The reduced CD11c 
could be the result of curcumin-induced AP-1 inhibition (99). 
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Mature or activated dendritic cells express elevated levels of co-
stimulatory and antigen presenting molecules on their surface such as CD86, 
CD83 and HLA-DR. If the antigen presenting machinery of DCs are impaired, 
they can not effectively engage the T cells to initiate a response.  HLA-DR 
surface expression is only significantly inhibited at the 30µM concentration of 
curcumin in LPS and TNF-α stimulated cells but in both concentrations 
stimulated with poly I:C show a significant reduction in HLA-DR surface 
expression. These data suggest curcumin may be interfering with the antigen 
presenting machinery of DCs by affecting the expression of key presentation 
molecules.  
Mature monocyte-derived DCs secrete IL-12, IL-10 and other pro-
inflammatory cytokines. Stimulated curcumin-treated DCs produce significantly 
lower levels of IL-12, IL-10, IL-6 and TNF-α when compared to the controls 
creating a Th2 permissive environment. Though the reduction of TNF-α was 
significant, they were not reduced to the levels of the unstimulated controls.  
These findings correlate with those from the study by Kim et al. (69) which shows 
curcumin prevents immunostimulatory function of murine bone marrow-derived 
cells. They along with others show curcumin is a potent inhibitor of NFκB and 
AP-1 activation as well as MAPK signaling (59, 149). This provides a reasonable 
explanation for the observed reduction of IL-12 and IL-10 levels in this study. 
This is the first study to report that curcumin decreases IL-10 in human DCs. 
TNF-α expression is controlled by other transcription factors such as 
lipopolysaccharide-induced TNF factor (LITAF) (136) or interferon regulatory-
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factor 3 (IRF3) (111) that may not be affected by curcumin, allowing the 
transcription of some TNF-α independent of the NFκB pathway. 
Capture and presentation of antigen is an important feature of DC biology. 
This provides the link between innate and adaptive immunity. Immature DCs are 
highly endocytic, a feature which is lost when cells become mature. We find 
curcumin reduces endocytosis in non-stimulated DCs. There is a significant 
decrease in dextran uptake by non-stimulated cells treated with curcumin similar 
to stimulated cells, but not in stimulated cells. There are conflicting reports on the 
effects of curcumin on antigen capture; a few studies show increased 
endocytosis, while others show suppression (44). Our findings indicate curcumin 
interferes with antigen handling in human DCs. 
Mature DCs travel to the lymph nodes where they present processed 
antigen to T cells. Migration towards chemo-attractants is a feature of mature 
DCs (81). They also secrete chemokines to attract responder cells to the site of 
injury or inflammation. Monocyte-derived DCs migrate in response to CCL19 or 
macrophage-inflammatory protein-3beta (MIP-3β) and CCL21 or exodus-2, which 
are expressed in the lymph nodes. Both chemokines bind to the CCR7 receptor 
on the DC surface. Though CCR7 expression is not affected, curcumin prevents 
migration towards CCL19 and CCL21 in a chemotaxis assay and also reduces 
the levels of chemokines fractalkine (CX3CL1) and interferon producing factor 
(IP-10). Both fractalkine and IP-10 attract inflammatory cells to sites of 
inflammation. Fractalkine attracts T cells, monocytes and microglia and mediates 
firm cell adhesion (17, 87). It also induces actin polymerization in human 
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dendritic cells (34). IP-10 is produced in response to IFNγ and LPS. This 
chemokine plays an important role in effector T cell trafficking (68). Poly I:C 
stimulated cells did not migrate in response to the chemokines, even in the 
absence of curcumin. By preventing DC migration, curcumin reduces the 
probability of the DC encountering T cells to initiate a specific immune response. 
Reduced chemokine secretion will stem the flow of inflammatory cell traffic to 
sites of inflammation. 
The mixed lymphocyte reaction (MLR) is used as the basic test of DC 
function since it measures their ability to stimulate proliferation of an allogeneic T 
cell population. Studies show curcumin can inhibit MLR (42, 57, 125, 153). 
Immature DCs will weakly stimulate proliferation, while the mature DCs will 
induce a significantly more robust response. This was observed in this study as 
there was a significant increase in the amount of T cell proliferation in the 
stimulated groups compared to the non-stimulated group. Increased expression 
of co-stimulatory markers on the surface of DCs is essential for T cell interaction 
and proliferation. Curcumin-treated DCs, both stimulated and non-stimulated, 
show muted T cell proliferation (Figures 19 and 20). Curcumin inhibits the Th1 
profile in antigen-primed CD4+ T cells while promoting the Th2 profile by 
suppressing IL-12 production in macrophages (66, 67). We observe that 
curcumin suppresses IL-12 production in DCs, but the cytokines produced after 
the MLR were mixed Th1/Th2. There was no clear delineation in either direction 
and the levels were very low. The low level of expression is most likely due to the 
reduced number of proliferated T cells generated by the co-culture. The mixed 
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phenotype could also be due to the ratio of DC to T cells used in the reaction 
(135). Curcumin-treated DCs induce a low level of proliferation and those 
proliferated cells express CD25 and Foxp3. This implies that curcumin is 
conferring a tolerogenic property to DCs. A measure of this propensity is the 
capacity to expand Foxp3 expressing lymphocytes (83, 139). It is suggested that 
an environment containing IL-10 can induce tolerogenic DCs (63, 89, 90) but in 
this study, the levels of IL-10 are only slightly (not significantly) elevated above 
control levels in both DC culture and co-culture, suggesting there may be an 
alternative mechanism at play.  
We show that curcumin is able to exert profound effects on the expression 
of genes involved with multiple signaling pathways associated with cytoskeleton 
organization and function. These pathways include axonal guidance signaling, 
glucocorticoid receptor signaling, actin cytoskeleton signaling. 
Immunofluorescence staining reveals curcumin interferes with cell actin based 
cell motility, attachment and microfilament organization on human dendritic cells 
in vitro. The actin inhibitor cytochalasin B was used as a control in most 
experiments to confirm the effects noted are most likely due to curcumin’s effects 
on f-actin organization.  
The regulation of the DC cytoskeleton is important in DC – T cell 
interactions (18). Little is known about the effect of curcumin on cytoskeletal 
rearrangement. One study reveals curcumin significantly alters the actin 
cytoskeleton in prostate cancer cells (56). Based on this premise, curcumin-
induced alterations in DC cytoskeleton could account for our observations. DC 
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migration involves regulation of the actin assembly. The cells must form 
protrusions such as filapodia and lamellapodia, form adhesions and retract its tail 
(80). Curcumin reduces expression of adhesion molecules and though 
lamellapodia and podosome formation appears to be unaffected, the cells are 
more rounded and we conclude less motile as there is the absence of the trailing 
edge seen in the non curcumin-treated cells and these cells do not seem to 
polarize in any particular direction. Cells were allowed to adhere to coated slides 
before curcumin treatment and LPS stimulation.  
For a more three-dimensional viewpoint, the cells that were imaged in 
suspension show a dramatic change in morphology. As the concentration of 
curcumin increases, the surface of the cell becomes more rounded and smooth 
and less elongated projections are visible. This results in an overall decrease in 
the cell surface area and so will affect the ability of the cell to interact with other 
cells such as T cells. The changes observed are similar to those induced by 
CytoB therefore we can infer that curcumin is inhibiting f-actin polymerization. 
Curcumin-treated DC show reduced attachment. They did not polarize or adhere 
strongly to the surface of the poly L-lysine coated slides as the non-treated cells 
did. The morphology was similar to that of the CytoB treated cells which clearly 
indicates the reduced attachment is due to inhibition of f-actin. 
The Rho family of GTPases is central to the reorganization of the actin 
cytoskeleton. Two key members are Rac1 and Cdc42. They participate in the 
control of cell migration, endocytosis and antigen presentation (43, 124). As 
determined by western blot analysis, curcumin reduces the activity of these 
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GTPases and so modulates the function of DCs in part through inhibition of actin 
signaling. The reduction in endocytosis observed in curcumin-treated cells may 
be due in part to the inhibition of actin pathway signaling. This is evidenced in 
figure 28 in which curcumin-treated cells show a similar level of endocytosis to 
that of CytoB-treated cells. 
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CONCLUSION 
Curcumin reduces the DC response to immune stimulants by reducing cell 
maturation and preventing normal cell function. It causes reduced expression of 
the surface markers CD86, CD84, HLA-DR, CD40 as well as the adhesion 
molecules CD11c and CD54 in response to a variety of external stimulants when 
compared to the untreated controls. Stimulant-induced cytokine and chemokine 
production was also reduced as a result of curcumin treatment. Functional 
aspects of DC maturation were also affected by curcumin. The high endocytic 
capacity of iDCs was significantly reduced in curcumin culture. Chemotaxis and 
DC-induced T cell proliferation was also abrogated. The few T cells that 
proliferated in co-culture expressed CD25 and Foxp3 indicating a regulatory 
population and curcumin may induce a tolerogenic DC. Curcumin affects cell 
architecture by inhibiting f-actin. 
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LIMITATIONS OF THE STUDY 
The major limitation of this study was the use of donors from Florida blood 
services. Without access to medical records or individual medical history, we are 
left to assume the participants were in good health. There is also the aspect of 
human subject variability. We elected to use a repeated measures analysis 
approach for data analysis in an effort to control for this variability. There is no 
established standard for the response of a donor to curcumin. The data was log 
transformed to ensure a normal distribution for statistical analysis. The age, 
gender and ethnicity of the donors may have played a role in the noted variation 
in responses. A larger sample size would be needed to address these aspects of 
the study.  
The concentrations of curcumin used in the study, though non-toxic, are 
not physiological. Due to the pharmacokinetic properties of curcumin and low 
bioavailability, the experimental concentrations can not be achieved through daily 
ingestion. In order to achieve these levels in the circulation, a special formulation 
may need to be engineered to prevent biodegradation. The method of delivery 
needs to be taken into account as well. When administered systemically 
curcumin will affect multiple cell types. To reproduce the DC-specific effects 
observed here, a formulation needs to be developed that will target curcumin 
specifically to DCs.  
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FUTURE DIRECTIONS 
  Further investigation into the generation of tolerogenic DCs by curcumin 
would be important in elucidating the immunosuppressive role of curcumin. This 
would include further characterization of the regulatory T cell population 
generated in co-culture. The DC to T cell ratio can be adjusted to examine the 
effects on the phenotype of these cells. This phenomenon needs to be examined 
in vivo using a mouse model of allergic asthma. If curcumin-DCs induce a 
regulatory T cell population, then the Th2 type response should be reduced. 
Using curcumin to target DCs and induce immune tolerance would make it an 
effective treatment for inflammation.   
Further investigation into the effects of curcumin on the actin cytoskeleton 
needs to be carried out as well. It would be important to determine if curcumin 
binds to any members of the actin cytoskeleton pathway. Disruption of f-actin 
organization affects cell attachment and function. Elucidation of the underlying 
mechanism is important for the development on novel curcumin based 
therapeutics. 
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Appendix A: List of Definitions 
 
Adaptive immunity: host defenses that are mediated by T and B cells after 
exposure to antigen that generate a specific or memory response or self/non-self 
recognition.    
Allergen: non-infectious antigen that induces a hypersensitivity or allergic 
reaction. 
Allogeneic: individuals of the same species that differ genetically. 
Antigen: any molecule that can bind to an antibody. Some have the ability to 
stimulate antibody production. 
Chemokine: small proteins that induce that mediate chemotaxis by regulating 
the expression of leukocyte integrins. 
Chemo-attractant: a substance that attracts leucocytes 
Chemotaxis: directional movement of cells. 
CD4: cluster of differentiation 4 is present on thymocytes, monocytes, 
macrophages and is a co-receptor of MHC Class II 
CD11c: cluster of differentiation 11c is present on myeloid cells and binds 
fibrinogen. It can be used to identify dendritic cells. 
CD80: cluster of differentiation 80 is present on dendritic cells and is a ligand for 
CD28 on T cells. It is important in the activation of naïve T cells through co-
stimulation (signal 2). 
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CD83: cluster of differentiation 83 is present on dendritic, B and Langerhans’ 
cells. It is a marker for activated dendritic cells and may assist in antigen 
presentation or cellular interactions that follow lymphocyte activation 
CD86: cluster of differentiation 86 is present on dendritic, monocytes and 
activated B cells and it is a ligand for CD28 on T cells. It is important in the 
activation of naïve T through co-stimulation (signal 2). 
CD54: cluster of differentiation 54 is present on hematopoietic and non-
hematopoietic cells. Also known as intercellular adhesion molecule (ICAM-1) and 
is involved in adhesion of neutrophils and is a receptor for rhinovirus. 
Cluster of differentiation (CD): a monocolonal antibody that identifies surface 
molecules, used to identify various immune cells. 
Cytokine: low molecular weight proteins that regulate the intensity and duration 
of the immune response by affecting the functions on other immune cells as well 
as the cell that produces it. 
Dendritic cell (DC): professional antigen presenting cell and the most potent 
activator of T and B cells. They are link the innate and adaptive immune systems 
and reside in tissues exposed to the external environment such as the skin, lungs 
and intestines.  
Dimethyl sulfoxide (DMSO): a chemical compound that is a polar aprotic 
solvent. It is an excellent solvent and cryoprotectant.  
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Flow cytometry: a technique used to count, examine and sort microscopic 
particles or cells suspended in a fluid stream. It uses the principles of light 
scattering, light excitation, and emission of fluorochrome molecules to generate 
specific multi-parameter data. 
Homotypic cluster formation: clustering of dendritic cells with each other that is 
an indicator of increased expression of adhesion molecules, chemokines and 
chemokine receptors.  
Human leukocyte antigen DR (HLA-DR): human leukocyte antigen -DR, the 
term for MHC in humans is required for antigen presentation to T cells.  
Innate immunity: non-specific host defense to invading pathogens such as 
bacteria, virus and allergens that includes various recognition systems such as 
toll-like receptors, endocytic, phagocytic and inflammatory mechanisms. The 
innate immune response does not increase with repeated exposure. 
Interferon gamma (IFNγ): cytokine that can induce cells to resist viral 
replication. It is produced by CD4+ Th1 cells and is a type II interferon and has 
antiviral, immunoregulatory, and anti-tumor properties. 
Interferon-inducing protein 10 (IP-10): chemokine that selectively attracts Th1 
lymphocytes and monocytes, and inhibits cytokine-stimulated hematopoietic 
progenitor cell proliferation. Also called CXCL10. 
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Interleukin 2 (IL-2): a T cell derived cytokine that stimulates growth and 
differentiation of T cells, B cells, NK cells, monocytes, macrophages. A central 
cytokine in the development of an adaptive immune response. 
Interleukin 4 (IL-4): a cytokine that is secreted by Th2 cells. It enhances both 
secretion and cell surface expression of IgE and IgG1. An important cytokine in 
allergic disease and has overlapping functions with IL-13. 
Interleukin 5 (IL-5): secreted by Th2 and mast cells that is a key mediator in 
eosinophil activation. An important cytokine in allergic disease. 
Interleukin 6 (IL-6): both a pro-inflammatory and anti-inflammatory cytokine. 
Important mediator of fever and of the acute phase response and secreted in 
response to activation of the innate immune system. High IL-6 It is associated 
with both Th1 and Th2 responses and low IL6 is associated with Treg responses. 
Interleukin 8 (IL-8): inflammatory chemokine produced by many cell types. 
Mainly functions as a neutrophil chemoattractant. 
Interleukin 10 (IL-10): secreted by Th0 cells blocks cytokine synthesis by Th1 
cells.  
Interleukin 12 p70 (IL-12p70): Th1 polarizing type cytokine secreted mainly by 
dendritic cells. Induces IFNγ production and proliferation/differentiation of Th1 
cells. 
Interleukin 13 (IL-13): secreted by Th2 cells, involved in the up-regulation of IgE 
secretion by B cells. An important cytokine in allergic disease. 
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Ligand: general term for a molecule recognized by a receptor. 
MHC Class II: major histocompatibility complex class II present on antigen 
presenting cells with the primary function to present peptide antigens, both self 
and non-self, to lymphocytes (T cells) for the purpose of eliciting an immune 
response.  
Mixed lymphocyte reaction (MLR): lymphocytes from two individuals are 
cultured together for several days in order to induce T cell proliferation. 
Monocyte: mononuclear phagocytic leukocyte  
Monocyte-derived dendritic cells (mdDCs): dendritic cells obtained by 
culturing CD14+ monocytes with granulocyte-macrophage colony-stimulating 
factor (GM-CSF) and interleukin 4 (IL4).  
Phagocytosis: the engulfment of particles, bacteria, cell debris, etc. by cells. A 
characteristic function of macrophages and dendritic cells.  
Polyinosinic-polycytidylic acid (Poly I:C): a commercially available synthetic 
double stranded RNA. A toll-like receptor 3 ligand that mimics viral infection and 
induces a Th1 response.  
T cells (TC): thymic lymphocytes that developed in the thymus. 
T cell proliferation: The reproduction of a T cell to produce two daughter cells. 
Naïve T helper lymphocyte (Th0): T lymphocytes that have never engaged a 
specific antigen.  
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T helper type 1 lymphocyte (Th1): T lymphocyte characterized by the cytokines 
they produce (especially IFNγ). An increase in Th1 cytokines are associated with 
autoimmune diseases. 
T helper type 2 lymphocyte (Th2): T lymphocyte characterized by the cytokines 
they produce (especially IL4, IL5, IL13). An increase in Th2 cytokines are 
associated with allergic diseases. 
Toll-like receptor (TLR): recognize pathogen-associated molecular patterns 
(PAMPs) that are expressed on infectious agents. They mediate the production 
of cytokines necessary for the development of effective immunity. 
Toll-like receptor 3 (TLR3): one of the toll-like receptors that recognizes double 
stranded RNA of viruses. 
Toll-like receptor 4 (TLR4): one of the toll-like receptors that recognize bacterial 
lpipoplysachharide on Gram-negative bacteria. 
T regulatory lymphocyte (Treg): T lymphocyte characterized by the cytokines 
they produce (IL10, TGF-β). They have the ability to inhibit T cell responses and 
induce tolerance. 
Tumor necrosis factor alpha (TNF-α): a pleiotropic inflammatory cytokine 
involved in apoptotic cell death/proliferation, differentiation, inflammation, tumor 
growth, and viral replication.  
Viability: ability of the cell to survive.  
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ABSTRACT 
Curcumin, a compound found in the Indian spice turmeric, has anti-
inflammatory and immunomodulatory properties, though the mechanism remains 
unclear. Dendritic cells (DCs) are important to generating an immune response 
and the effect of curcumin on human DCs has not been explored. The role 
curcumin in the DC response to bacterial and viral infection was investigated in 
vitro using LPS and Poly I:C as models of infection. CD14+ monocytes, isolated 
from human peripheral blood, were cultured in GM-CSF- and IL-4-supplemented 
medium to generate immature DCs. Cultures were incubated with curcumin, 
stimulated with LPS or Poly I:C and functional assays were performed. Curcumin 
prevents DCs from responding to immunostimulants and inducing CD4+ T cell 
proliferation by blocking maturation marker, cytokine and chemokine expression 
and reducing both migration and endocytosis. These data suggest a therapeutic 
role for curcumin as an immune suppressant. 
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INTRODUCTION 
Curcumin is a biologically active compound found in the Indian spice 
turmeric. It belongs to a family of compounds called curcuminoids and usually 
comprises about 3% of turmeric powder. The spice is commonly used as a 
preservative for foods and a yellow dye or coloring for textiles and as an 
ingredient in pharmaceuticals and cosmetics. For many centuries curcumin has 
been used as an antiseptic, analgesic, appetite suppressant, anti-inflammatory 
agent, anti-oxidant, anti-malarial, and insect repellant [1,2]. The pharmacological 
potential of curcumin is under investigation. Researchers found that it has anti-
inflammatory, anti-oxidant, anti-parasitic, anti-viral, and anti-cancer properties [3–
6]. It targets transcription factors, cytokines, cell adhesion molecules, surface 
receptors, growth factors, and kinases, among other molecules [7–10], and 
directly binds to a variety of surface and intracellular proteins causing direct 
cellular pathway inhibition or activation of secondary cellular responses [2,11]. 
Dendritic cells are the sentinels of the immune system and regulate the 
immune response. Immature or resting dendritic cells reside in peripheral organs 
where they monitor the surrounding tissue for invading microorganisms. They 
alert the immune system to the presence of pathogens by engulfing them, 
processing the foreign proteins and presenting the peptide fragments on their 
surface. After DCs are activated, they mature and migrate to the lymphoid tissue 
where they prime T lymphocytes and stimulate a specific or adaptive response  
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[12,13]. Maturation of dendritic cells involves changes in gene expression and 
activation of signaling pathways, and it is reasonable to hypothesize that 
curcumin can modulate some of these pathways and thereby prevent DC 
maturation and alter function. While a study by Kim et al. reveals that curcumin 
impairs the immunostimulatory function of murine dendritic cells [14], its effects 
on human dendritic cells remain unknown. Curcumin’s effects on human DC 
stimulation are examined in this study. Modulating the DC response could 
provide an effective approach to treat and control unwanted inflammation. 
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MATERIALS AND METHODS 
Reagents. Curcumin (from Curcuma longa) was obtained from Sigma 
Aldrich (St. Louis, MO) and dissolved in DMSO. Buffy coats were obtained from 
Florida Blood Services (St. Petersburg, Florida). Six donors, four males and two 
females, in good health and ranging in age from 18 to 50 were used for the 
study. Cell isolation reagents CD14 microbeads and CD4+ T cell isolation kit 
were obtained from Miltenyi Biotec (Auburn, CA). Histopaque_-1077 and was 
obtained from Sigma Aldrich and recombinant human cytokines GM-CSF and IL-
4 were obtained from PeproTech (Rocky Hill, NJ). All other cell culture reagents 
were obtained from GIBCO Invitrogen (Carlsbad, CA). LPS, poly I:C and PHA 
were obtained from Sigma Aldrich (St. Louis, MO). CFSE and Alexa-647 
conjugated dextran (molecular weight 10,000) were obtained from Molecular 
Probes Invitrogen (Carlsbad, CA). LINCOplex Multiplex cytokine assay kits were 
purchased from Millipore (Temecula, CA). All CD11c, HLA-DR, CD86, CD83, and 
CD54 antibodies were obtained from BD Biosciences (San Jose, CA). CCL19 
and CCL21 were obtained from PeproTech (Rocky Hill, NJ). 
Cell Isolation and Culture. CD14+ monocytes were isolated and cultured 
as described by Picki et al. [15]. Briefly, leukocytes were extracted from buffy 
coats using Histopaque-1077. Monocytes expressing CD14 were positively 
selected with magnetic microbeads. Purity (>90%) was verified by staining with 
anti-CD14 antibodies and analyzing by flow cytometry. Cells were cultured at 1 ×  
 116
Appendix C (Continued) 
 
106 cells/ml in complete RPMI (10% FBS, 1% pen/strep, 10 mM Hepes, non-
essential amino acids and 5 mM sodium pyruvate) with 20 ng/ml each rh IL-4 and 
GM-CSF for 5–6 days, (supplementing at day three with fresh medium). Non- 
adherent and loosely adherent cells were removed on day five for analysis or 
stimulation. On day 5, more than 90% of the harvested cells expressed CD11c 
and HLA-DR. CD4+ T cells were isolated from the CD14+ fraction remaining 
after monocyte depletion and cultured in complete RPMI. Purity was confirmed 
by flow cytometry after CD4 staining.  
Cell Treatment and Stimulation. Curcumin was added to cell culture (1 × 
106 cells/ml and 3 ml/well in 6-well plates) at concentrations of 20 or 30 µM. 
DSMO was used as a control. After a 1 h incubation, LPS (1 µg/ml) or Poly I:C 
(25 µg/ml) was added to the appropriate wells. Control wells received neither. 
Cultures were incubated overnight at 37 ºC and 5% CO2/95% air. Cell viability 
was 95% ± 0.06 after 24 h of culture under all conditions listed above as 
determined by a viability assay using 7AAD incorporation.  
Flow Cytometry. Cells were collected, washed and stained with 
fluorochrome-conjugated antibodies specific for DC surface markers. Cells were 
analyzed using the Becton Dickenson (BD) Canto II with HTS sampler and BD 
FACSDivaTM software.  
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Cytokine Assay. Culture supernatant was collected and cytokine levels 
measured using the LINCOplex multiplex assay. Assays were performed in 
duplicate according to the manufacturer’s instructions.  
Chemotaxsis Assay. Treated and stimulated cells were collected, counted 
and re-suspended at a concentration of 1 × 106 cells/ml. Fifty microliters of cell 
suspension was placed in the upper chambers of 5 µm pore size polycarbonate 
filter inserts in a 96-well microchemotaxis plate (Chemicon). The lower chambers 
contained 40 µl of either CCL19 or CCL21 in 150 µl of medium. Control wells had 
medium only. Input wells (in triplicate) contained 1 × 104 cells in the lower 
chambers without chemokines. Cells were incubated at 37 ºC and 5% CO2/95% 
air overnight. Migration was stopped by the removal of the inserts. Polystyrene 
beads (1 × 104) were added to each well (lower chamber) and analyzed by flow 
cytometry. The number of cells in each sample and input was calculated using 
the following equation: Number of cells/well = (number of cell events × number of 
bead events) × 104. Input cells = average [number of input cells/well × 5 (dilution 
factor)]. The percentage migration for each sample (% input) is determined by 
the following equation: Percent migration = (migrating cells × input cells) × 100.  
Mixed Lymphocyte Reaction. CFSE labeling of CD4+ T cells was carried  
out by resuspending cells in 1ml PBS containing 5% (v/v) FBS. 1.1 µl of the 
CFSE stock (5 µM) was diluted in 110 µl of PBS and quickly mixed with the cell 
suspension. After a 5 min incubation at room temperature, the reaction was  
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stopped by adding ten volumes of room temperature PBS containing 5% (v/v) 
FBS and centrifuging at 300g for 5 min at 20 ºC. Cells were washed twice and 
resuspended in complete medium (1 × 106 cells/ml). The dendritic cell-T cell co-
culture was set up at a ratio of 1:16. Curcumin treated and stimulated DCs were 
removed from culture and placed in 96-well plates in triplicate (6.25 × 103 cells in 
100 µl per well). T cells (100 µl) were added to each well and cultures incubated 
at 37 ºC and 5% CO2 /95% air for 5 days. CFSE fluorescence intensity was 
measured by flow cytometry using the BD Canto II with HTS attachment and BD 
FACS Diva software.  
Endocytosis Assay. Cells were collected, washed and incubated with 1 
mg/ml (per 1 × 106 cells) Alexa-647 conjugated dextran at either 4 ºC or 37 ºC for 
1 h. Cells were washed with cold PBS and either analyzed by flow cytometry or 
plated on gelatin coated cover slips and imaged by confocal microscopy. The 
change in mean fluorescence intensity (MFI) is calculated as the difference 
between the MFI of 37 ºC and 4 ºC cultures.  
Microscopy. All bright field images were captured using the 4× objective of 
an Olympus IX71 inverted fluorescent microscope with an attached DP70 
camera. Fluorescent images were captured using the 63x objective of a Leica 
scanning confocal microscope.  
Statistical Analysis. Data was log transformed to ensure normal 
distribution. Significance was determined using paired t tests (repeated  
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measures) for planned comparisons with modified Bonferroni correction. Data 
are presented as the average of six donors. Error bars represent SEM with p 
values less than 0.05 considered statistically significant. 
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RESULTS AND DISCUSSION 
This is the first study to examine the effects of curcumin on human 
dendritic cells in vitro. Donors for the study were selected at random and 
supplied by Florida Blood Services, St. Petersburg, Florida. The concentrations 
of curcumin used were based on those previously found efficacious in the 
literature and confirmed not to be toxic to the cells by viability assays (data not 
shown). All cultures remained more than 90% viable up to 24 h after curcumin 
addition. The pharmacokinetics and pharmacodymanics of curcumin have been 
more extensively studied in rodents than in humans [16]. From the limited human 
data available, the low bioavailability of curcumin limits its clinical usefulness 
when administered orally. High doses can be administered without adverse 
effects but the systemic distribution may not be sufficient to exert 
pharmacological activity. Combining curcumin with other compounds, or using 
drug delivery systems such as liposomes and nanoparticles provide an 
alternative approach to overcome these issues [17–19]. The immunostimulants 
lipopolysacchaide (LPS) and polyinosinic:polycytidylic acid (poly I:C) were used 
in this study to independently stimulate DC activation. LPS via the toll like 
receptor 4 (TLR4) pathway and poly I:C mimics viral infections through TLR3. 
These compounds were chosen to ensure the immunostimulatory effects were 
not TLR dependent. Observed stimulant effects were found to be significant with 
p values <0.05 by paired t test compared to non-stimulated controls. 
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Curcumin Prevents Increased Maturation Marker Expression and Cytokine 
Secretion 
Mature dendritic cells express elevated levels of co-stimulatory and 
antigen presenting molecules such as CD86, CD83 and HLA-DR on their 
surface. If the antigen presenting machinery of DCs are impaired, they can not 
effectively engage the T cells to initiate a response. Stimulated curcumin-treated 
DCs do not significantly increase their surface expression of CD86 and CD83 
above the control (Fig. 1A). HLA-DR surface expression is not significantly 
inhibited by 20 µM curcumin. We can surmise that curcumin affects the antigen 
presenting machinery by reducing co-stimulatory molecule expression but not the 
antigen presenting molecules. Mature monocyte-derived DCs secrete IL-12, IL-
10, and other inflammatory cytokines. Stimulated curcumin-treated DCs produce 
significantly lower levels of IL-12, IL-10, and TNFα when compared to the 
controls (Fig. 1B) creating a Th2 permissive environment. IL-6 was also 
significantly reduced by curcumin (data not shown). Though the reduction of 
TNFα was significant, they were not reduced to the levels of the controls. These 
findings correlate with those from the study by Kim et al. [14] which shows 
curcumin prevents immuno-stimulatory function of murine bone marrow-derived 
cells. They along with others show curcumin is a potent inhibitor of NF-κB and 
AP-1 activation as well as MAPK signaling [20,21]. This provides a reasonable 
explanation for the observed reduction of IL-12 and IL-10 levels in this study.  
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TNFα expression is controlled by other transcription factors such as 
lipopolysaccharide- induced TNF factor (LITAF) [22] or interferon regulatory-
factor 3 (IRF3) [23] that may not be affected by curcumin, allowing the 
transcription of some TNFα independent of the NF-κB pathway. 
 
Curcumin Prevents DC-Induced CD4+ T Cell Proliferation in the Mixed 
Lymphocyte Reaction 
The mixed lymphocyte reaction (MLR) is used as the basic test of DC 
function since it measures their ability to stimulate proliferation of an allogeneic T 
cell population. Studies show curcumin can inhibit MLR [24–27]. Immature DCs 
will weakly stimulate proliferation, while the mature DCs will induce a significantly 
more robust response (Fig. 2A). Increased expression of co-stimulatory markers 
is essential for T cell interaction and proliferation. Curcumin-treated DCs, both 
stimulated and non-stimulated, show muted T cell proliferation (Fig. 2A). These 
observations and those in Fig. 1A imply there are factors at play other than the 
expression levels of co-stimulatory and antigen presenting molecules. The 
regulation of the DC cytoskeleton is important in DC–T Cell interactions [28]. 
Little is known about the effect of curcumin on cytoskeletal rearrangement. One 
study reveals curcumin significantly alters the actin cytoskeleton in prostate 
cancer cells [29]. Based on this premise, curcumin-induced alterations in DC 
cytoskeleton could account for the observations in Fig. 2A. Analysis of the CD4 T  
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Cell cytokines produced in the MLR revealed a Th2–biased response evidenced 
by the increase in the IL-4:IFNγ ratio between untreated and curcumin treated 
cells (Fig. 2B). 
 
Curcumin Reduces Endocytosis 
Capture and presentation of antigen is an important feature of DC biology. 
This provides the link between innate and adaptive immunity. Immature DCs are 
highly endocytic, a feature which is lost when cells become mature. We find 
curcumin reduces endocytosis in non-stimulated DCs (Fig. 2C and D). There is a 
significant decrease in dextran uptake by non-stimulated cells treated with 
curcumin similar to stimulated cells, but not in stimulated cells. There are 
conflicting reports on the effects of curcumin on antigen capture; a few studies 
show increased endocytosis, while others show suppression [30]. Our findings 
indicate curcumin interferes with antigen handling in human DCs. 
 
Curcumin Prevents Homotypic Clustering and Surface Adhesion Marker 
Expression 
DCs aggregate in clusters in response to stimuli as a visual sign of 
maturation [31]. Cluster formation correlates with increased CD86, CD54, and 
CD80 expression. Here we show curcumin impairs homotypic DC cluster  
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formation in response to both LPS and poly I:C in a concentration-dependent 
manner (Fig. 3A). Adhesion molecules such as ICAM-1 (CD54) are important in 
cellular interactions and in generating T cell response. Murine antigen presenting 
cells (APCs) deficient in ICAM-1 have impaired ability to induce T cell responses 
[32,33]. CD11c, a member of the integrin family of proteins, is also important for 
cell attachment and found in high levels on DCs. Curcumin significantly reduces 
expression of both markers on the DC surface (Fig. 3B and C). The reduced 
CD11c could be the result of curcumin-induced AP-1 inhibition [34]. 
 
Curcumin Prevents DC Migration and Chemokine Secretion 
Mature DCs travel to the lymph nodes where they present processed antigen to 
T cells. Migration towards chemoattractants is a feature of mature DCs [35]. They 
also secrete chemokines to attract responder cells to the site of injury or 
inflammation. Monocyte-derived DCs migrate in response to CCL19 or 
macrophage-inflammatory protein-3beta (MIP-3b) and CCL21 or exodus-2, which 
are expressed in the lymph nodes. Both chemokines bind to the CCR7 receptor 
on the DC surface. CCR7 expression is not affected by curcumin (data not 
shown). Curcumin prevents migration towards CCL19 and CCL21 in a 
chemotaxis assay (Fig. 4A) and also reduces the levels of chemokines 
fractalkine (CX3CL1) and interferon producing factor (IP-10) (Fig. 4B and C). 
Both fractalkine and IP-10 attract inflammatory cells to sites of inflammation. Poly  
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I:C stimulated cells did not migrate in response to the chemokines, even in the 
absence of curcumin (data not shown). By preventing DC migration, curcumin 
reduces the probability of the DC encountering T cells to initiate a specific 
immune response. Reduced chemokine secretion will stem the flow of 
inflammatory cell traffic to sites of inflammation. 
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 CONCLUSIONS AND PERSPECTIVES 
Curcumin acts in several ways as an immune suppressor of human 
peripheral CD14+ monocyte-derrived DCs. It renders them non-responsive to the 
immuno-stimulants LPS and poly I:C by reducing expression of co-stimulatory 
and antigen presentation molecules expression and dampening the Th1-type 
response while promoting a Th2 permissive environment. It also reduces 
migration and adhesion molecule expression and reduces DC-induced 
proliferation of allogeneic CD4+ T cells. The inhibition of transcription factors NF-
κB and AP-1 and other cell signaling pathways by curcumin provide a plausible 
explanation for most of observations; however curcumin may be targeting other 
essential cellular pathways as well. Based on our observations and reports from 
other studies, we speculate curcumin may be disrupting the antigen handling and 
presenting machinery of DCs in addition to transcription factor and signaling 
pathway inhibition [30]. Elucidation of the mechanism of action of curcumin 
immunosuppression could lead to clinical applications of this novel anti-
inflammatory agent. 
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FIGURE LEGENDS 
 
Fig. 1. Curcumin reduces maturation marker expression (A) and cytokine 
Production (B) in human monocyte-derived dendritic cells. Surface marker 
expression is measured as mean fluorescence intensity (MFI) by flow cytometry. 
Cytokine levels were measured from culture supernatant using a multiplex assay 
kit and expressed as log concentration. *Significance by one-tailed t-test of 
planned comparisons p < 0.05. 
 
Fig. 2. Curcumin reduces DC-induced proliferation of allogenieic CD4+ T cells (A) 
and promotes a Th2-permissive environment with an increased IL4:IFNγ ratio (B) 
in mixed lymphocyte reaction. Curcumin also reduces the endocytic capability of 
DCs. Endocytosis of fluorescently labeled dextran was measured by change in 
mean fluorescence intensity (MFI) between cells incubated at 37 ºC and 4 ºC (C) 
and imaged by confocal microscopy of a representative donor (D). *Significance 
by one-tailed t-test of planned comparisons p < 0.05. 
 
Fig. 3. Curcumin prevents homotypic clustering of DCs in response to stimuli (A) 
and reduces surface adhesion molecules CD54 (B) and CD11c (C). Surface 
marker expression is measured as mean fluorescence intensity (MFI) by flow 
cytometry. *Significance by one-tailed t-test of planned comparisons p < 0.05. 
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Fig. 4. Curcumin prevents DC migration towards CCL19 and CCL21 (A) and 
chemokine secretion in culture (B, C). Chemotaxis assay performed in 96-well 
microchemotaxis plate with 5 lm pore size polycarbonate filters. Chemokine 
levels were measured from culture supernatant using a multiplex assay kit. 
*Significance by one-tailed t-test of planned comparisons p < 0.05. 
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FIGURES 
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Figure 3. 
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Figure 4.
DMSO Cur 20 µM LPS Cur 20 µM+LPS
0
10
20
30
40
Medium
CCL21
CCL19
*
*
P
er
ce
nt
 M
ig
ra
tio
n
A 
B C
Experimental Conditions 
Fractalkine
No Stim LPS
0.0
0.5
1.0
1.5
Lo
g 
C
on
cn
et
ra
tio
n
IP-10
No Stim LPS
0
1
2
3
4
5
DMSO
Cur 20µM
*
Lo
g 
C
on
ce
nt
ra
tio
n
  
 
 
 
 
ABOUT THE AUTHOR 
 
 Shawna Ann Shirley was born in St. Andrew, Jamaica in 1980. She 
earned a Bachelor’s degree in Biochemistry with a minor in Chemistry from the 
University of the West Indies, Mona campus (Honors) in 2001. She then became 
a teacher of Mathematics and Science at Ardenne High School in St. Andrew 
Jamaica. After two years in the profession she decided to pursue higher 
education in research. She moved to Tampa, Florida in 2003 to join the 
Multidisciplinary Biomedical Sciences Ph.D. program at the University of South 
Florida, College of Medicine. She earned a Master of Science in Medical 
Sciences in 2007 and went on to complete the Ph.D. degree in Medical Sciences 
with a specialty cognate in Molecular Medicine.  Shawna is married to Karl 
Gilman, a teacher who is currently pursing a career as a mental health counselor. 
 
